

INFORMAȚII PERSONALE

TOMULEASA CIPRIAN



✉ ciprian.tomuleasa@umfcluj.ro

Sexul M | Data nașterii [REDACTED] | Naționalitatea RO

EXPERIENȚA PROFESIONALĂ

- 2022 – PREZENT **MEDIC PRIMAR HEMATOLOG**
INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA
- 2021 – PREZENT **SECRETAR AL COMITETULUI DE TERAPII CELULARE**
MINISTRUL SĂNĂTĂȚII, ROMÂNIA
- 2017 – PREZENT **SECRETAR AL COMITETULUI DE HEMATOLOGIE**
MINISTRUL SĂNĂTĂȚII, ROMÂNIA
- 2017 – PREZENT **ȘEF DE LUCRĂRI – DEPARTAMENTUL DE HEMATOLOGIE**
UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
- 2017 – 2022 **MEDIC SPECIALIST HEMATOLOG**
INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA
- 2022 - PREZENT **CERCETĂTOR ȘTIINȚIFIC GRAD I**
CENTRUL DE CERCETĂRI MEDFUTURE, UMF CLUJ-NAPOCA, ROMÂNIA
- 2015-2020 **CERCETĂTOR ȘTIINȚIFIC GRAD III**
CENTRUL DE CERCETĂRI PENTRU GENOMICA FUNCȚIONALĂ, BIOMEDICINĂ ȘI MEDICINĂ TRANSLAȚIONALĂ, CLUJ-NAPOCA, ROMÂNIA
- 2013-2016 **MEDIC REZIDENT – HEMATOLOGIE**
INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA
- 2013-2015 **CERCETĂTOR ȘTIINȚIFIC**
CENTRUL DE CERCETĂRI PENTRU GENOMICA FUNCȚIONALĂ, BIOMEDICINĂ ȘI MEDICINĂ TRANSLAȚIONALĂ, CLUJ-NAPOCA, ROMÂNIA
- 2011-2013 **POSTDOCTORAND**
JOHNS HOPKINS SCHOOL OF MEDICINE, BALTIMORE, MD, USA
- 2009-2011 **ASISTENT CERCETARE – DEPARTAMENTUL DE HISTOLOGIE**
UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
- 2007-2011 **ASISTENT CERCETARE – DEPARTAMENTUL DE IMUNOLOGIE**
UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA

EDUCAȚIE ȘI FORMARE

- SEPTEMBRIE 2018 **TRAINING ÎN IMUNOTERAPII PENTRU BOLI HEMATOLOGICE**
DEPARTAMENTUL DE IMUNOLOGIE, INSTITUTUL ONCOLOGIC NAȚIONAL, TOKYO, JAPONIA
- OCTOMBRIE 2017 **TRAINING ÎN MANAGEMENTUL COMPLICAȚIILOR POST-TRANSPLANT ALLOGENEIC DE CELULE STEM HEMATOPOIETICE**
DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM, INSTITUTUL ONCOLOGIC NAȚIONAL,

	TOKYO, JAPONIA
NOIEMBRIE 2017	TRAINING ÎN TRANSPLANTUL ALLOGENEIC DE CELULE STEM HEMATOPOIETICE PENTRU MALIGNITĂȚI DE CELULE T DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM, INSTITUTUL ONCOLOGIC NAȚIONAL, TOKYO, JAPONIA
2016-2017	TRAINING ÎN CERCETARE CLINICĂ ȘI TRIALURI CLINICE SOCIETATEA EUROPEANĂ DE HEMATOLOGIE
IUNIE-OCTOMBRIE 2015	TRAINING ÎN TRANSPLANTUL HAPLOIDENTIC DE CELULE STEM DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM ȘI TERAPII CELULARE, INSTITUTUL ONCOLOGIC ANDERSON, HOUSTON, STATELE UNITE ALE AMERICII
2013-2016	REZIDENȚIAT INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA
2011-2013	POSTDOCTORAT ÎN BIOLOGIE TUMORALĂ DEPARTAMENTUL DE MEDICINĂ INTERNĂ, COMPARTIMENTUL DE GASTROENTEROLOGIE ȘI HEMATOLOGIE, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, BALTIMORE, STATELE UNITE ALE AMERICII
2011-2013	DOCTORAT DEPARTAMENTUL DE IMUNOLOGIE, UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
2005-2011	STUDENT MEDICINIST UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
2001-2005	ELEV COLEGIUL NAȚIONAL CALISTRAT HOGAȘ, PIATRA NEAMȚ, ROMÂNIA

COMPETENȚE PERSONALE

Limba maternă **ROMÂNĂ**

Alte limbi străine cunoscute

	INTELEGERE		VORBIRE		SCRIERE
	Ascultare	Citire	Participare la conversație	Discurs oral	
ENGLEZĂ	C1/2	C1/2	C1/2	C1/2	C1/2
FRANCEZĂ	B1/2	B1/2	B1/2	B1/2	B1/2

Niveluri: A1/2: Utilizator elementar - B1/2: Utilizator independent - C1/2: Utilizator experimentat
Cadrul european comun de referință pentru limbi străine

MERITE ÎN DOMENIUL MEDICINII

- Izolarea in vitro a primei linii de celule stem canceroase din România, în martie 2010, ca student în anul IV la medicină (**Tomuleasa C**, Soritau O, Rus-Ciucu D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestinal Liver Dis. 2010; 19(1):61-7)
- Coautor în lucrări științifice publicate de un laureat de premiu Nobel:
 1. KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma. Sergiu Pasca, Ciprian Tomuleasa, Gabriel Ghiaur, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, Aaron Ciechanover, Hermann Einsele. Frontiers in Oncology, 2019, 9:1137.
 2. Targeting ubiquitination in myeloid malignancies. From basic research to drug discovery in MDS and AML. Rares Drula, Sabina Iluta, Diana Gulei,

Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, Aaron Ciechanover, Ciprian Tomuleasa. Blood Reviews, 2022

- Membru al grupului de lucru de diagnostică in vitro al OMS (Geneva, 2020)
- INDEX HIRSCH: 29

MEMBRU ÎN SOCIETĂȚI PROFESIONALE

2022 – PREZENT	Societatea de Oncologie Hematologică
2019 – PREZENT	Societatea Japoneză de Hematologie
2017 – PREZENT	Societatea Română de Hematologie
2016 – PREZENT	Societatea Română de Transplant Medular (Membru Fondator)
2014 – PREZENT	Societatea Europeană de Hematologie
2014 – PREZENT	Societatea Americană de Hematologie
2008 – PREZENT	Societatea Română de Radioterapie și Oncologie Medicală

INFORMATII SUPLIMENTARE

PARTICIPANT ACTIV CU PREZENTAREA ORALĂ SAU POSTER:

- NAȚIONALE: 35
- INTERNAȚIONALE: 41 – Australia (Melbourne), Austria (Vienna), Belgia (Anvers), China (Beijing), Croația (Zagreb), Cipru (Nicosia), Republica Cehă (Brno), Danemarca (Copenhagen), Egipt (Cairo), Franța (Angers, Bordeaux, Champéry, Paris), Germania (Berlin, Jena, Lindau), Grecia (Ioannina), Ungaria (Budapesta, Pécs, Szeged), Islanda (Reykjavik), Italia (Bologna, Milano, Roma, Viareggio), Japonia (Osaka, Tokyo), Lituania (Druskininkai), Moldova (Chișinău), Olanda (Duin et Kruidbergeweg), Polonia (Poznan, Krakow), Portugalia (Faro), România (București, Cluj-Napoca, Iași, Poiana Brașov, Piatra Neamț, Predeal, Sinaia, Timișoara, Tulcea), Rusia (Moscova), Serbia (Novi Sad), Africa de Sud (Cape Town, Stellenbosch), Spania (Barcelona, Madrid, Sitges, Valencia), Elveția (Geneva), Taiwan (Taipei), Regatul Unit al Marii Britanii (Edinburgh, London), Statele Unite ale Americii (Atlanta, Boston, Baltimore, Honolulu, Houston, Orlando, San Diego, San Francisco)
- SPEAKER INVITAT:
 - DECEMBRIE 2021 – Ohio State University, Columbus, OH, Statele Unite Ale Americii
 - MAI 2021 – Reykjavik University, Reykjavik, Islanda
 - MARTIE 2018 – University Of Iceland, Reykjavik, Islanda
 - OCTOMBRIE 2017 – Osaka International Cancer Center, Osaka, Japonia
 - SEPTEMBRIE 2017, OCTOMBRIE 2019 – People's Liberation Army Navy Hospital, Beijing, China
 - FEBRUARIE 2017 – University Of The Western Cape, Cape Town, Africa De Sud
 - NOIEMBRIE 2016 – Stellenbosch University, Stellenbosch, Africa De Sud

ORGANIZATOR EVENIMENTE ȘTIINȚIFICE:

NOIEMBRIE 2021	Keynote speaker in hematology series – Prof. Dr. Dieter Hölzer (University of Frankfurt, Germania)
19-20 SEPTEMBRIE 2021	Insights In Hematology, ediția a 5-a - hibrid (președinte congres)
19-20 SEPTEMBRIE 2020	Insights In Hematology, ediția a 5-a - online (președinte congres)
NOIEMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Gabriel Ghiaur (Johns Hopkins University, Baltimore, MD, Statele Unite ale Americii)
OCTOMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Erik Aerts (University of Zürich, Zürich, Elveția)
OCTOMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Hermann Einsele

- (University of Würzburg, Würzburg, Germania)
- IULIE 2019** Keynote speaker in hematology series – Prof. Dr. Anders Tveita
(University of Oslo, Oslo, Norway)
- 12-14 MAI 2019** Insights In Hematology, ediția a 4-a (președinte congres)
- DECEMBRIE 2018** Keynote speaker in hematology series – Aaron Ciechanover
- 9-10 MARTIE 2018** Insights In Hematology, ediția a 3-a (președinte congres)
- 9 SEPTEMBRIE 2017** Beijing-Cluj Hematology Summit Forum
- 10-11 MARTIE 2017** Insights In Hematology, ediția a 2-a (președinte congres)
- 11-12 MARTIE 2016** Insights In Hematology (președinte congres)
- 11 SEPTEMBRIE 2015** Nanotechnology in leukemia chemotherapy (președinte congres)

EXPERIENȚA EDITORIALĂ:

- 2021** editor invitat (special issue) – Frontiers in Medicine, IF: 5.091
- 2020** editor invitat (special issue) – Frontiers in Medicine, IF: 5.091
- 2019** editor invitat (special issue) – Frontiers in Pharmacology, IF: 3.92
- 2019 – PREZENT** membru comitet editorial – Annals of Translational Medicine, IF: 3.689
- 2018 - PREZENT** membru comitet editorial – Journal of Clinical Medicine, IF: 5.688
- 2018 - PREZENT** membru comitet editorial – Medicine and Pharmacy Reports

GRANTURI DE CERCETARE COORDONATE:

NR.	FINANȚARE	PROIECT	ROL ÎN GRANT	PERIOADA	BUGET (EUR)
1	Romanian – European Economic Space (EES) International Research Grant Competition 2014-2016	Nanotechnology Approach in Acute Myeloid Leukemia Management – acronim: NanoLAM	MANAGER GRANT din parte Institutului Oncologic „Ion Chiricuță” INVESTIGATOR PRINCIPAL: Prof. Dr. Andrei Cucuianu, Universitatea de Medicină și Farmacie “Iuliu Hațieganu” Cluj-Napoca, România INVESTIGATOR CO-PRINCIPAL: Prof. Dr. Emmet McCormack – University of Bergen, Norvegia	2014-2016	110.000
2	Grant intern pentru tinerii cercetători al Universității de Medicină și Farmacie „Iuliu Hațieganu” 2014-2015	Cell and molecular mechanisms of primary myelofibrosis	INVESTIGATOR PRINCIPAL	2014-2015	8.000
3	Romanian– European Economic Space	Innovative Nanoparticle-based Chemotherapy	INVESTIGATOR PRINCIPAL INVESTIGATOR CO-PRINCIPAL	2015-2016	41.000

	(EES) International Grant Competition 2015-2016	for Acute Myeloid Leukemia - Collaboration with Norway (University of Bergen) – acronim: NanoChemotherapy	Prof. Dr. Emmet McCormack – University of Bergen, Norvegia		
4	Young Research Team Competition, awarded by the Romanian Research Ministry and Education 2016-2017	Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site	INVESTIGATOR PRINCIPAL	2016-2017	125.000
5	Grant intern pentru studenți al Universității de Medicină și Farmacie „Iuliu Hațieganu”, 2015-2016	A synthetic lethality approach in the acute myeloid leukaemia chemotherapy: PARP inhibitors plus anthracycline plus decitabine vs anthracycline plus decitabine –in vitro efficacy testing	MENTOR GRANT pentru stud. Grigore Gafencu	2015-2016	2.000
6	Grant intern pentru studenți al Universității de Medicină și Farmacie „Iuliu Hațieganu”, 2015-2016	The efficacy of pirfenidone in primary myelofibrosis	MENTOR GRANT pentru stud. Sonia Selicean	2016-2017	2.000
7	Romania - P.R. China International Bilateral Collaboration competition 2016-2017	Invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation	INVESTIGATOR PRINCIPAL INVESTIGATOR CO-PRINCIPAL: Prof. Dr. Jianlian Shen – Navy General Hospital, Beijing, China	2016-2017	9.533
8	FDI competition of the National Council for the Financing of University Education 2017	Modern training for healthcare professionals affiliated to the departments of hematology, oncology and bone marrow transplantation	INVESTIGATOR PRINCIPAL	2017	43.826
9	FDI competition of the National Council for the Financing of University Education 2018	Correlation of the educational curricula in molecular medicine and translational onco-hematology with the European	INVESTIGATOR PRINCIPAL	2018	38.922

		workforce demand			
10	National Research Ministry for Frontiers Research 2017-2022	Multifunctional magnetoplasmonic nanoparticles for point of care applications in acute myeloid leukemia, acronym: NanoTEX	MANAGER GRANT din parte Institutului Oncologic „Ion Chiricuța” INVESTIGATOR PRINCIPAL: Prof. Dr. Emil Burzó, Universitatea Babeș-Bolyai, Cluj-Napoca	2018- 2022	180.000 (valoare totală – 1.800.000)
11	Invited Professor 2018 Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine, from the National Research Ministry	Invited Professor Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine.	INVESTIGATOR PRINCIPAL	2018	2.619
12	Romania - P.R. China International Bilateral Collaboration competition 2018-2019	Experimental Immunotherapy for hematological malignancies	INVESTIGATOR PRINCIPAL INVESTIGATOR CO-PRINCIPAL: Prof. Dr. Liren Qian, Navy General Hospital, Beijing, China	2018 - 2019	8.609
13.	FDI competition of the National Council for the Financing of University Education 2019	Increase of the competitiveness of medical education by correlating the curricula to Anglo-Saxon standards	INVESTIGATOR PRINCIPAL	2019	41.916
14.	Romanian – European Economic Space (EES) International Grant Competition – Collaboration with Iceland; 2020-2022	HE-RO-IS strategic collaboration in hematology – Iceland collaboration (Reykjavik University) – acronym: HERO	INVESTIGATOR PRINCIPAL INVESTIGATOR CO-PRINCIPAL: Prof. Dr. Olafur Eysteinn Sigurjonsson, Reykjavik University, Islanda	2020 - 2021	144.153
15.	Novo Nordisk Haemophilia Foundation International Grant 2020-2022	Strengthen haemophilia care in the north and establish a national registry in Romania – Romania 3	INVESTIGATOR PRINCIPAL (Societatea Română de Hematologie)	2020 - 2021	81.903
16.	National Research Ministry for Postdoctoral Research 2020-2022	Evaluation of the effect of human chorionic gonadotrophin in stem cell transplantation as a new method of	MENTOR GRANT pentru Dr. Andrei Cismaru - PhD	2020 - 2022	51.667

		pretransplant mobilization			
17.	National Research Ministry for Postdoctoral Research 2020-2022	New generation preclinical model for evaluating the therapeutic role of microRNA-505-5p for metastasis limitation in melanoma	MENTOR GRANT pentru Diana Gulei - PhD	2020 - 2022	51.667
18.	National Research Ministry for Young Research Teams 2020-2022	Supporting a team of young researchers in creating an independent research program based on the use of the Sleeping Beauty protocol for developing CAR T cells – acronym: SEATTLE	INVESTIGATOR PRINCIPAL	2020 - 2022	93.001
19.	Romania – Wallonia/Belgium International Bilateral Collaboration competition 2020-2022	Consolidation of the Wallonia-Romania collaboration for setting of new standard operation procedures (SOP) in immunotherapy	INVESTIGATOR PRINCIPAL INVESTIGATOR CO-PRINCIPAL: Prof. Jo Caers, University of Liege, Belgium	2021-2022	10.561
20.	National Research Ministry for Exploratory Research 2020-2023	Harnessing the ubiquitin-proteasome system (UPS) to suppress tumor's growth via manipulating generation of NF-kB – acronym: ROME	INVESTIGATOR CO-PRINCIPAL INVESTIGATOR PRINCIPAL: Prof. Dr. Aaron Ciechanover – laureat premiul Nobel pentru Chimie - 2004	2021-2024	250.000
21.	National Research Ministry for Exploratory Research 2020-2023	The role of stromal CYP26 in retinoid homeostasis in the context of myelodysplastic syndromes pathogenesis and response to treatment - acronym: LONDON	INVESTIGATOR CO-PRINCIPAL INVESTIGATOR PRINCIPAL: Prof. Dr. Gabriel Ghiaur	2021 -2024	250.000
22.	Novo Nordisk Haemophilia Foundation International Grant 2022-2024	Strengthen haemophilia care in the north-eastern part of Romania and in Moldova and establish a registry in Moldova – Romania 4	INVESTIGATOR PRINCIPAL (Societatea Română de Hematologie)	2022 - 2024	102.779
23.	Grant intern pentru studenți al Universității de Medicină și	Study of iCasp9 transfected anti-CD41 CAR-T cells for acute megakaryoblastic	MENTOR GRANT pentru stud. Dávid Kegyes	2022-2024	2.000

	Farmacie „Iuliu Hațieganu”, 2022-2024	leukemia			
BUGET TOTAL DE LA 2014 PÂNĂ ÎN PREZENT:					1.651.156 EUR

TRIALURI CLINICE – EXPERIENȚA:

No.	Disease	Title	Sponsor / International investigator / Period	Role in the study
1.	Leucemie acuta mieloida FLT3-pozitiva, prima linie	Phase III clinical trial investigating quizartinib plus standard chemotherapy versus standard chemotherapy , for patients with therapy-naïve FLT3-IDT positive acute myeloid leukemia	Daiichi-Sankyo, 2018-2020	Co-investigator al Institutului Oncologic Ion Chiricuta Cluj Napoca (Principal investigator: Dr. Delia Dima)
2.	Limfoame cu celule T, prima linie	Prospective, longitudinal, multinational registry of patients with newly diagnosed peripheral T cell lymphoma	Associazione Angela Serra per la Ricerca sul Cancro Centro Oncologico Modenese - Medical Oncology, School of Medicine University of Modena and Reggio Emilia Modena, Italy, 2018 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
3.	Hemoglobinurie paroxistica nocturna, prima linie	A phase III randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and eculizumab in subjects with paroxysmal nocturnal hemoglobinuria	Samsung Bioepis, 2019-2022	Co-investigator al Institutului Oncologic Ion Chiricuta Cluj Napoca (Principal investigator: Dr. Delia Dima)
4.	Leucemie acuta mieloida, pacienti	Real world treatment patterns and clinical	Abbvie, 2019-2020	Investigator Principal al

	ineligibili de tratament intensiv	outcomes in unfit AML patients receiving first line systemic treatment or best supportive care (study H19-743)		Institutului Oncologic Ion Chiricuta
5.	Limfom cu celule de manta, pacienti ineligibili de tratament intensiv	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation	BeiGene, 2021 - present	Co-investigator for Ion Chiricuta Oncology Institute Cluj Napoca (Principal investigator: Dr. Delia Dima)
6.	Mielofibroza primara, prima linie	A Phase 3 Randomized, double-blind, active-control study of CPI-0610 and ruxolitinib versus placebo and ruxolitinib in JAKi treatment naïve MF patients (MANIFEST-2)	Constellation Pharmaceuticals, 2021 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
7.	Afectiuni hemato-oncologice	Evaluation of the safety of pegfilgrastim in the primary prophylaxis of febrile neutropenia in patients with myelosuppressive chemotherapy	Totem Communication, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
8.	Hemofilie A	A multinational, open-label, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (FRONTIER-2)	Novo Nordisk Pharmaceuticals, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta Institute Cluj Napoca
9.	Limfom follicular, refractar / recidivat	Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry	European Hematology Association (EHA) Lymphoma Group, 2022 – present	Investigator Principal al Institutului Oncologic Ion Chiricuta
10.	Mielofibroza primara	A multi-country, real-world study to explore treatment patterns, effectiveness and healthcare resource utilization for patients	Abbvie, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta

		diagnosed with myelofibrosis through chart review (METER)		
11.	Policitemia vera	A Prospective, Multicenter, Non-interventional, Observational, Post-authorization Safety Study of Ropeginterferon alfa-2b in Polycythemia Vera Patients (Besremi-PASS)	AOP Orphan, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
12.	Mielom multiplu refractar ./ recidivat	A phase 3, two-stage, randomized, multicenter, open label study comparing CC-92480, bortezomib and dexamethasone (480 Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma.	Bristol Myers Squibb, 2022-present	Investigator Principal al Institutului Oncologic Ion Chiricuta
13.	Limfom follicular si limfom de zona marginala, refractar sau recidivat	A retrospective multicenter, non-interventional study to generate a real-world comparator cohort in adult patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma	Bristol Myers Squibb, 2022-present	Investigator Principal al Institutului Oncologic Ion Chiricuta

CĂRȚI PUBLICATE:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015. ISBN 978-606-8699-74-5.
2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrenghea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-30-7.
3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-69-7.
4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-98-7.
5. NEOPLASMELE MIELOPROLIFERATIVE. Cristina Bagacean, Iulia Berceanu, Delia Dima, Bogdan Fetica, Jean-Cristophe Ianotto, Mariana Patiu, Adrian Tempescul, **Ciprian Tomuleasa**, Adrian Trifa, Mihnea Zdrenghea. Sub redactia Mihnea Zdrenghea. Editura Casa Cartii de Stiinta, Cluj Napoca, 2017. ISBN 978-606-17-1135-2.
6. GHID DE TRANSPLANT MEDULAR. Alina Tanase, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca,

2017.

CAPITOLE DE CĂRȚI PUBLICATE:

 • **CĂRȚI INTERNAȚIONALE:**

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. In "CANCER RESEARCH AND CLINICAL TRIALS IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.
2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, **Ciprian Tomuleasa**, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, 2017.
3. NON-CODING RNAs IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, **Ciprian Tomuleasa**, Diana Gulei, George Adrian Calin, Ioana Berindan-Neagoe. In "Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy", book edited by Dan Simionescu and Agneta Simionescu, ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, 2017.
4. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**, Horia Bumbea, Cristina Bagacean. In "New Approaches to the Management of Primary and Secondary CNS Tumors is published " Intech, ISBN 978-953-51-3052-9, 2017.
5. THE USEFULNESS OF BIOMARKERS FOR DIAGNOSIS. Patric Teodorescu, Sergiu Pasca, **Ciprian Tomuleasa**. In "Pineal region lesions. Management strategies and controversial issues. Springer – Zurich, 2020, ISBN 978-3-030-50912-5.

 • **CĂRȚI NAȚIONALE:**

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE. **Ciprian Tomuleasa**, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
2. ROLUL PROGNOSTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.
3. REGIMURI DE CONDITONARE. Alina Tanase, **Ciprian Tomuleasa**. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.
4. EVALUAREA CARDIACA PENTRU TRANSPLANTUL DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Sergiu Pasca, Anca Bojan, Delia Dima. In "MANUAL DE CARDIOONCOLOGIE". Cristina Vlad, Dan Radulescu, Simona Dragan, Claudia Burz. Editura Medicala Universitara Iuliu Hatieganu 2020.

ARTICOLE PUBLICATE:

1. HORIZON 2020. FUNDS TO HELP EASTERN EUROPE CLOSE THE GAP. Cristian Berce, **Ciprian Tomuleasa**, Radu Meza. Nature 2017, 541(7636):157-157. **impact factor: 38.138.**
2. PATIENT SELECTION FOR CAR-T OR BITE THERAPY IN MULTIPLE MYELOMA. WHICH TREATMENT FOR EACH PATIENT? David Keyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigiu, Delia Dima, Diana Gulei, Alina Tanase, Hermann Einsele, Stefan Ciurea, Ciprian Tomuleasa, Jo Caers. Journal of Hematology and Oncology 2022, **impact factor: 17.388**, in press.
3. THE INTERPLAY BETWEEN CANCER CELLS, MACROPHAGES AND NATURAL KILLER CELLS MAY ACTUALLY DECIDE THE OUTCOME OF THERAPY WITH SORAFENIB. **Tomuleasa C**, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. Hepatology. 2014; 60(1):430. **impact factor: 12.008.**
4. HUMAN BILE CONTAIN MICRORNA-LADEN EXOSOMES THAT CAN BE USED FOR CHOLANGIOCARCINOMA DIAGOSIS. Ling Li, David Masica, Masaharu Ishida, **Ciprian Tomuleasa**, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne-Marie Lennon, Payal Saxena, Jean-Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Haoran Peng, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M. Selaru. Hepatology. 2014;60(3):896-907. **impact factor: 12.008.**
5. CANCER-ASSOCIATED RS6983267 SNP AND ITS ACOMPANYING RNA CCAT2 INDUCE MYELOID MALIGNANCIES VIA UNIQUE SNP-SPECIFIC RNA MUTATIONS. Maitri Shah, Valentina Pileczki, Linda Fabris,

- Manuela Ferracin, Roxana Redis, Maria Ciccone, Xinna Zhang, Masayoshi Shimizu, Cristian Rodriguez-Aguayo, Maria Angelica Cortez, Cristina Ivan, Taghi Manshouri, Steliana Calin, Jan Parker-Thornburg, Asha Multani, James Welsh, Marcos Estecio, Hui Ling, **Ciprian Tomuleasa**, Delia Dima, Hui Yang, M. James You, Srdan Verstovsek, Milan Radovich, Katy Rezvani, Elizabeth Shpall, Leonard Girnita, Ioana Berindan-Neagoe, Riccardo Fodde, Carlos Bueso-Ramos, Mihai Gagea, Guillermo Garcia-Manero, Ines Almeida, Daniela Nedelcu, Muharrem Muftuoglu, Pinaki Banerjee, Mustafa Badiwi, George Calin. *Genome Research* 2017, **impact factor: 11.351**.
6. CONTINUOUS RENAL REPLACEMENT THERAPY IN CYTOKINE RELEASE SYNDROME FOLLOWING IMMUNOTHERAPY OR CELLULAR THERAPIES? Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Dana Tomescu, Delia Dima, Ecaterina Scarlatescu, Alina Tanase, Anca Colita, Olafur Eysteinn Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. *Journal of Immunotherapy of Cancer*, 2020, in press. **impact factor: 9.9**.
 7. DIVINE MESSENGERS: ARE EXOSOMES THE HERMESES OF MODERN MOLECULAR ONCOLOGY? **Ciprian Tomuleasa**, Cornelia Braicu, Pamela Monroig, Andrei Cucuianu, Ioana Berindan-Neagoe, George A. Calin. *Cell Death Differentiation*. 2015; 22(1):34-45. **impact factor: 8.371**.
 8. NANOMEDICINE FOR ACUTE LYMPHOBLASTIC LEUKEMIA DETECTION AND TREATMENT. Andra Sorina Tatar, Timea Simon, Simion Astilean, **Ciprian Tomuleasa**, Sanda Boca. *Journal of Controlled Release*, 2016; 238:123-38. **impact factor: 8.407**.
 9. UNEXPLAINED HEMORRHAGIC SYNDROME? CONSIDER ACQUIRED HEMOPHILIA A OR B. Catalin Constantinescu, Ciprian Jitaru, Sergiu Pasca, Delia Dima, Noemi Dirzu, Daniel Coriu, Joanna Zdziarska, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Blood Reviews*, 2021, in press. **impact factor: 8.25**.
 10. TARGETING UBIQUITINATION IN MYELOID MALIGNANCIES. FROM BASIC RESEARCH TO DRUG DISCOVERY IN MDS AND AML. Rares Drula, Sabina Iluta, Diana Gulei, Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, Aaron Ciechanover, **Ciprian Tomuleasa**. *Blood Reviews*, 2022, in press. **impact factor: 8.25**.
 11. ANTIBODY CONJUGATED, RAMAN-TAGGED HOLLOW GOLD NANOSPHERES FOR SPECIFIC TARGETING AND MULTIMODAL DF/SERS/TPE-FLIM IMAGING OF CD19(+) B LYMPHOBLASTS. Timea Nagy-Simon, Andra-Sorina Tatar, Ana-Maria Craciun, Adriana Vulpoi, Maria-Ancuta Jurj, Adrian Florea, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Simion Astilean, Sanda Boca. *ACS Applied Materials & Interfaces*, in press. **impact factor: 7.145**.
 12. THE ROLE OF MICRORNAS IN THE PATHOGENESIS OF HIV-RELATED LYMPHOMAS. Ravnit Grewal, Andrei Cucuianu, Carmen Swanepoel, Delia Dima, Bobe Petrushev, Bogdan Pop, Ioana Berindan-Neagoe, **Emmanuel Akin Abayomi, Ciprian Tomuleasa**. *Critical Reviews in Clinical Laboratory Sciences* 2015, 52(5):232-41. **impact factor: 7.00**.
 13. PSEUDOGENE INTS6P1 REGULATES IT'S CONGNATE GENE INTS6 THROUGH COMPETITIVE BINDING OF MIR-17-5P IN HEPATOCELLULAR CARCINOMA. Haoran Peng, Masaharu Ishida, Atsushi Saito, Atsushi Kamiya, James P. Hamilton, Rongdang Fu, Alexandru V. Olaru, Fangmei An, Irinel Popescu, Razvan Iacob, Simona Dima, Sorin T. Alexandrescu, Razvan Grigorie, Anca Nastase, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Florin Graur, Florin Zaharia, Michael S. Torbenson, Esteban Mezey, Minqiang Lu, Florin M. Selaru. *Oncotarget* 2015; ;6(8):5666-77. **impact factor: 6.63**.
 14. TRANSIENT LEUKEMIA OF DOWN SYNDROME. Sas Valentina, Blag Cristina, Zaharie Gabriela, Andronic-Gorcea Nicolae, Pasca Sergiu, Petrushev Bobe, Chis Irina, Marian Mirela, Dima Delia, Zdrenghia Mihnea, Berindan-Neagoe Ioana, Popa Gheorghe, Man Sorin, Colita Anca, Stefan Cristina, Kojima Seiji, **Tomuleasa Ciprian**. *Critical Reviews in Clinical Laboratory Sciences*, 2019, in press. **impact factor: 6.481**.
 15. MICRORNAS ASSOCIATED WITH A GOOD PROGNOSIS OF ACUTE MYELOID LEUKEMIA AND THEIR EFFECT ON MACROPHAGE POLARIZATION. Alexandra Neaga, Cristina Bagacean, Adrian Tempescul, Laura Jimbu, Oana Mesaros, Cristina Lucia Blag, **Ciprian Tomuleasa**, Corina Bocsan, Mihaela Gaman, Mihnea Zdrenghia. *Frontiers in Immunology*, 2020, in press, **impact factor: 6.429**.
 16. A COMPREHENSIVE PICTURE OF EXTRACELLULAR VESICLES AND THEIR CONTENT. Ancuta Jurj, Oana Zanoaga, Cornelia Braicu, Vladimir Lazar, **Ciprian Tomuleasa**, Alexandru Irimie, Ioana Berindan-Neagoe. *Cancers*, 2020, in press. **impact factor: 6.102**.

17. CHARACTERISTICS OF DENTAL RESIN BASED COMPOSITES IN LEUKEMIA SALIVA: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. *Biomedicines* 2021, in press. **impact factor: 6.081.**
18. MIR-543 REGULATES THE EPIGENETIC LANDSCAPE OF MYELOFIBROSIS BY TARGETTING TET1 AND TET2. Enrique Fuentes-Mattei , Recep Bayraktar, Taghi Manshouri, Andreia Silva, Cristina Ivan, Diana Gulei, Linda Fabris, Nayra Soares, Pilar Mur, Cristina Perez-Caro, Elizabeth Torres-Claudio, Mihnea Dragomir, Adriana Grisselle Badillo, Erik Knutsen, Pranav Narayanan, Leonard Golfman, Masayoshi Shimizu, Xinna Zhang, Wanke Zhao, Wanting Ho, Marcos R. H. Estecio, Geoffrey Bartholomeusz, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Patrick Zweidler-McKay, Zeev Estrov, Joe Zhao, Srdan Verstovsek, George A. Calin, Roxana Redis. *Journal of Clinical Investigation Insights*, 2020, in press, **impact factor: 6.014.**
19. PATTERNS OF HEALTHCARE RESOURCE UTILIZATION (HRU) IN UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING FIRST LINE SYSTEMIC TREATMENT OR BEST SUPPORTIVE CARE (BSC): A MULTICENTER INTERNATIONAL STUDY (CURRENT). T Ito, D Sanford, **C Tomuleasa**, HH Hsiao, LJ Enciso Oliveira, AK Enjeti, Conca A Gimenez, T Barnal del Castillo, L Girsova, MP Martelli, B Guvenc, CN Bui, A Delgado, Y Duan, B Garbavo Guijarro, C Llamas, JH Lee. *Value in Health*, 2021, in press, **impact factor: 6.**
20. SERS-BASED EVALUATION OF METHYLATION PROGRESSION IN CLONAL LEUKEMOGENESIS OF DOWN SYNDROME. Vlad Moisoiu, Valentina Sas, Andrei Stefancu, Stefania D. Iancu, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Alina-Andreea Zimta, Adrian B. Tigu, Delia Dima, Patric Teodorescu, Cristina Turcas, Cristina Blag, Delia Dima, Gheorghe Popa, Smaranda Arghirescu, Sorin Man, Anca Colita, Nicolae Leopold, **Ciprian Tomuleasa**. *Frontiers in Bioengineering and Biotechnology*, 2021, in press, **impact factor: 5.89.**
21. NOVEL INSIGHTS INTO TRIPLE-NEGATIVE BREAST CANCERS, THE EMERGING ROLE OF ANGIOGENESIS, AND ANTIANGIOGENIC THERAPY. Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, **Ciprian Tomuleasa**, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe. *Expert Reviews in Molecular Medicine*. 2016; 18:e18. **impact factor: 5.71.**
22. CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. **Ciprian Tomuleasa**, Shigeo Fuji, Cristian Berce, Anca Onaciu, Sergiu Chira, Bobe Petrushev, Wilhelm Thomas Micu, Vlad Moisoiu, Sergiu Pasca, Ciprian Osan, Catalin Constantinescu, Ancuta Jurj, Laura Pop, Ioana Berindan-Neagoe, Delia Dima, Shigehisa Kitano. *Frontiers in Immunology*, in press. **impact factor: 6.429.**
23. THE POTENTIAL EQUIVALENTS OF TET2 MUTATIONS. Sergiu Pasca, Ancuta Jurj, Mihnea Zdrenghia, **Ciprian Tomuleasa**. *Cancers*, 2021, in press. **impact factor: 6.126.**
24. EFFECTS OF LEUKEMIA SALIVA ON DENTAL RESIN-BASED COMPOSITES: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. *Biomedicines*, 2021, in press. **impact factor: 6.081.**
25. THE THERAPEUTIC MANIPULATION OF IL-10 AND PROGRAMMED DEATH LIGAND-1 IN ACUTE MYELOID LEUKAEMIA: THE ADVANTAGE OF TARGETING BOTH PD-L1/PD-L2-PD-1 AND IL-10-IL-10R PATHWAYS. Laura Jimbu, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, **Ciprian Tomuleasa**, Delia Dima, Corina Bocsan, Mihnea Zdrenghia. *Pharmaceuticals*, 2021, in press. **impact factor: 5.863.**
26. APPROACH TO THE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENT. Valentina Sas, Vlad Moisoiu, Patric Teodorescu, Sebastian Tranca, Laura Pop, Sabina Iluta, Sergiu Pasca, Cristina Blag, Sorin Man, Andrei Roman, Catalin Constantinescu, Ioana Rus, Mihail Buse, Cosmin Lisencu, Bogdan Fetica, Mirela Marian, Cristina Selicean, Ioana Berindan-Neagoe, Bobe Petrushev, Horia Bumbea, Alina Tanase, Mihnea Zdrenghia, Shigeo Fuji, Shigehisa Kitano, **Ciprian Tomuleasa**, Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation. *Journal of Clinical Medicine*, 2019, in press. **impact factor: 5.688.**
27. DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY USING FLOW CYTOMETRY ON FINE NEEDLE ASPIRATION. REPORT ON 269 CASES. Carla Griesel, Minodora Desmirean, Tonya Esterhuizen, Sergiu Pasca, Bobe Petrushev, Cristina Selicean, Andrei Roman, Bogdan Fetica, Carmen Swanepoel, **Ciprian Tomuleasa**, Ravnit Grewal. *Journal of Clinical Medicine*, 2020, in press, **impact factor: 5.688.**
28. MICRORNA-155-5P PLAYS A CRITICAL ROLE IN TRANSIENT LEUKEMIA OF DOWN SYNDROME BY TARGETING TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBERS. Valentina Sas, Sergiu Sas, Ancuta Jurj, Laura Pop, Liviuta Budisan, Hideki Muramatsu, Delia Dima, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Anca Onaciu, Raluca Munteanu, Diana Gulei, Alina-Andreea Zimta, Alexander von Gamm, Cristina

- Blag, Gheorghe Popa, Smaranda Arghirescu, Margit Serban, Sorin Man, Mirela Marian, Cristian Berce, Anca Colita, Alina Tanase, Mihnea Zdrenghea, Seiji Kojima, Diana Gulei, Yoshiyuki Takahashi, **Ciprian Tomuleasa**. Cellular Physiology and Biochemistry, 2020, in press. **impact factor: 5.5**.
29. HODGKIN'S LYMPHOMA AND ITS ASSOCIATION WITH EBV AND HIV INFECTION. Grewal Ravnit, Alexandra Irimie, Naidoo Nasheen, Mohamed Nooroudien, Petrushev Bobe, Chetty Manogari, **Tomuleasa Ciprian**, Abayomi Emmanuel Akinola. Critical Reviews in Clinical Laboratory Sciences, in press. **impact factor: 5.340**.
 30. MAGNETIC RESONANCE IMAGING-BASED DIAGNOSIS OF PROGRESIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT WITH NON-HODGKIN'S LYMPHOMA FOLLOWING THERAPY WITH CYCLOPHOSPHAMIDE, HYDROXYDAUNORUBICIN, VINCRIStINE, PREDNISONE AND RITUXIMAB. Delia Dima, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Stefan Florian, Bobe Petrushev, Ioana Berindan-Neagoe, Andrei Cucuianu. Cancer. 2014;120(24):4005-6. **impact factor: 5.2**.
 31. CLINICAL APPROACH TO THE PATIENT IN CRITICAL CONDITION FOLLOWING IMMUNOTHERAPY AND/OR STEM CELL TRANSPLANTATION. GUIDELINE FOR THE ON-CALL PHYSICIAN. Catalin Constantinescu, Constantin Bodolea, Sergiu Pasca, Delia Dima, Ioana Rus, Tiberiu Tat, Patric Teodorescu, Patriciu Achimas-Cadariu, Alina Tanase, **Ciprian Tomuleasa**, Hermann Einsele. Journal of Clinical Medicine, 2019, in press. **impact factor: 5.306**.
 32. MECOM, HBS1L-MYB, THRB-RARB, JAK2 and TERT polymorphisms defining predisposition to myeloproliferative neoplasms - a study on 939 patients. Adrian Trifa, Claudia Banescu, Anca Bojan, Alina Popa, Florin Tripon, Delia Dima, Viola Maria Popov, Stefan Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo Mihaila, Nicoleta Berbec, Ion Macarie, Andrei Colita, Maria Iordache, Alina Catana, Marius Farcas, **Ciprian Tomuleasa**, Kinga Vasile, Cristina Truica, Adriana Todinca, Lavinia Muntean, Raluca Manolache, Horia Bumbea, Ana-Maria Vladareanu, Mihaela Dervesteanu, Cristina Ciufu, Radu Popp. American Journal of Hematology 2017, in press. **impact factor: 5.275**.
 33. SERS LIQUID BIOPSY: AN EMERGING TOOL FOR MEDICAL DIAGNOSIS. Vlad Moisoiu, Stefania Dana Iancu, Andrei Stefancu, Tudor Moisoiu, Barbara Pardini, Mihnea Paul Dragomir, Nicolae Crisan, Lucretia Avram, Dana Crisan, Iulia Andras, Daniela Fodor, Carmen Socaciu, Zoltán Bálint, **Ciprian Tomuleasa**, Nicolae Leopold, Florin Elec. Colloids and Surfaces B: Biointerfaces, 2021, in press. **impact factor: 5.268**.
 34. ASSESSING MEASURABLE RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA. BCR-ABL IS IN THE AVANT-GARDE OF MOLECULAR HEMATOLOGY. Vlad Moisoiu, Delia Dima, Lorand Parajdi, Sergiu Pasca, Patric Teodorescu, Radu Precup, **Ciprian Tomuleasa**, Simona Soverini. Frontiers in Oncology, 2019, in press, **impact factor: 5.165**.
 35. LET'S TALK ABOUT BITES AND OTHER DRUGS IN THE REAL LIFE SETTING FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Dalma Deak, Cristina Pop, Andreea-Alina Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Delia Dima, Patric Teodorescu, Catalin Constantinescu, Mihnea Zdrenghea, Daniel Coriu, Alina Tanase, Ioana Berindan-Neagoe, Delia Dima, Hermann Einsele, **Ciprian Tomuleasa**. Frontiers in Immunology, 2019, in press. **impact factor: 5.165**.
 36. BASOPHILIA SUGGESTS AN 'ACCELERATED PHASE' IN THE EVOLUTION OF CHRONIC CALR-POSITIVE PRIMARY MYELOFIBROSIS TOWARDS ACUTE MYELOID LEUKEMIA. Jerome Dobrowolski, Sergiu Pasca, Patric Teodorescu, Ioana Rus, Cristina Selicean, Ana Maria Rosu, Ioana Berindan-Neagoe, Bogdan Fetica, Adrian Trifa, Anca Bojan, Mihnea Zdrenghea, Bobe Petrushev, **Ciprian Tomuleasa**, Delia Dima. Frontiers in Oncology, 2019, in press, **impact factor: 5.165**.
 37. LEAM VERSUS BEAM VERSUS CLV CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY LYMPHOMAS. RETROSPECTIVE COMPARISON OF TOXICITY AND EFFICACY ON 222 PATIENTS, ON BEHALF OF THE ROMANIAN SOCIETY FOR BONE MARROW TRANSPLANTATION. Andrei Colita, Anca Colita, Horia Bumbea, Adina Croitoru, Carmen Orban, Lavinia Eugenia Lipan, Oana Gabriela Craciun, Dan Soare, Cecilia Ghimici, Raluca Manolache, Ionel Gelatu, Ana Maria Vladareanu, Patric Teodorescu, Delia Dima, Sergiu Pasca, Anca Lupu, Daniel Coriu, **Ciprian Tomuleasa**, Alina Tanase. Frontiers in Oncology 2019; in press. **impact factor: 5.165**.
 38. PROTEIN DYSREGULATION IN GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. Liren Qian, Delia Dima, Jian Cen, Cristian Berce,

- Lajos Raduly, Alina Tanase, Bobe Petrushev, Ioana Berindan-Neagoe, Alexandru Irimie, Ancuta Jurj, Jian Liang Shen, **Ciprian Tomuleasa**. *Oncotarget*, in press. **impact factor: 5.168.**
39. GENETICALLY ENHANCED T LYMPHOCYTES AND THE INTENSIVE CARE UNIT. Tiberiu Tat, Huming Li, Catalin Constantinescu, Anca Onaciu, Sergiu Chira, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Cristian Berce, Sebastian Tranca, Delia Dima, Ioana Berindan-Neagoe, Jianliang Shen, **Ciprian Tomuleasa**, Liren Qian. *Oncotarget* 2018, in press. **impact factor: 5.168.**
 40. MOBILE HEALTH TECHNOLOGY FOR THE PERSONALIZED THERAPY OF HEMOPHILIA. Noemi Dirzu, Ionut Hotea, Melen Brinza, Mareike-Catrina Peters, Krisztina Gal, Louis Popescu, Cristina Blag, Mirela Marian, Eva Pal, Marilena Stanescu, Diana Cenariu, Cristina Tarniceriu, Margit Serban, Delia Dima, Daniel Coriu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2021, in press, **impact factor: 5.091.**
 41. COAGULOPATHY IN ACUTE PROMYELOCYTIC LEUKEMIA: CAN WE GO BEYOND SUPPORTIVE CARE? Bryan C. Hambley, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Medicine*, 2021, in press. **impact factor: 5.091.**
 42. MODERN APPROACHES TO HEMOPHILIA MANAGEMENT: GENE THERAPY AND BEYOND. Daniel Coriu, Noemi Dirzu, Alina-Andreea Zimta, Bryan C. Hambley, Laszlo Nemes, Xiaojing Liu, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2022, in press. **impact factor: 5.091.**
 43. RESULTS OF A TWO-ARM PHASE II CLINICAL TRIAL USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Sameh Gaballa, Isabell Ge, Riad El-Fakih, Jonathan E. Brammer, **Ciprian Tomuleasa**, Sa A. Wang, Dean Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee Hammerstrom, Lindsey Lombardi, Gheath Al-atrash, Martin Korbbling, Oran Betul, Partow Kebraie, Sairah Ahmed, Nina Shah, Katyoun Rezvani, David Marin, Qaiser Bashir, Amin Alousi, Yago Nieto, Muzaffar Qazilbash, Chitra Hosing, Uday Popat, Elizabeth J. Shpall, Issa Khouri, Richard E. Champlin, Stefan O. Ciurea. *Cancer*, 2016; 122(21):3316-3326. **impact factor 5.068.**
 44. EXOSOME-CARRIED MICRORNA-BASED SIGNATURE AS A CELLULAR TRIGGER FOR THE EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA INTO RICHTER SYNDROME. Ancuta Jurj, Laura Pop, Bobe Petrushev, Delia Dima, Ioana Rus, Adrian Trifa, Bogdan Fetica, Grigore Gafencu, Sonia Selicean, Daiana Temian, Cristian Berce, Alexandra Sacu, Alin Moldovan, Andrei Colita, Horia Bumbea, Alina Tanase, Angela Dascalescu, Nicolae Leopold, Emil Burzo, Mihnea Zdrengha, Rares Stiufiuc, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *Critical Reviews in Clinical Laboratory Sciences*, 2018, in press. **impact factor: 5.34.**
 45. PERIODONTAL DISEASE MIGHT BE A RISK FACTOR FOR GRAFT VERSUS HOST DISEASE. A SYSTEMATIC REVIEW. Alexandru Mester, Andra Mester, Sebastian Tranca, **Ciprian Tomuleasa**, Alina Tanase. *Critical Reviews in Hematology and Oncology*, 2020, in press. **impact factor: 5.012.**
 46. HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND SUBSEQUENT ACUTE HEPATIC FAILURE IN A MULTIPLE MYELOMA PATIENT FOLLOWING COMBINATION THERAPY WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE. Catalin Constantinescu, Bobe Petrushev, Ioana Rus, Horia Stefanescu, Otilia Frasinariu, Simona Margarit, Delia Dima, **Ciprian Tomuleasa**. *Journal of Personalized Medicine*, 2022, in press. **impact factor: 4.945**
 47. MEDICAL APPLICATIONS OF HYDROGEN IN HEMATOLOGICAL DISEASES. Liren Qian, Zhengcheng Wu, Jian Cen, Sergiu Pasca, **Ciprian Tomuleasa**. *Oxidative Medicine and Cellular Longevity*, 2019, in press. **impact factor: 4.868.**
 48. MACROPHAGE POLARIZATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: NURSE-LIKE CELLS ARE THE CARETAKERS OF CLL CELLS. Oana Mesaros, Laura Jimbu, Alexandra Neaga, Cristian Marian Popescu, Iulia Berceanu, **Ciprian Tomuleasa**, Bogdan Fetica, Mihnea T. Zdrengha. *Biomedicine*, 2020, submitted for publication. **impact factor: 4.717.**
 49. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. *Frontiers in Immunology*, **impact factor: 4.716.**
 50. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. *Frontiers in Oncology* 2020, in press, **impact factor: 4.716.**

51. TRANSFORMING GROWTH FACTOR BETA-MEDIATED MICROMECHANICS MODULATES DISEASE PROGRESSION IN PRIMARY MYELOFIBROSIS. Patric Teodorescu, Sergiu Pasca, Ancuta Jurj, Jon Petur Joelsson, Sonia Selicean, Cristian Moldovan, Raluca Munteanu, Anca Onaciu, Mihail Buse, Bogdan Tigu, Sebastian Rauch, Rares Stiufiuc, Minodora Desmirean, Delia Dima, Jon Thor Bergthorsson, Bobe Petrushev, Cristian Berce, Stefan Ciurea, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2020, in press, **impact factor 4.658**.
52. AZACYTIDINE PLUS OLAPARIB FOR RELAPSED ACUTE MYELOID LEUKEMIA, INELIGIBLE FOR INTENSIVE CHEMOTHERAPY, DIAGNOSED WITH A SYNCHRONOUS MALIGNANCY. Sabina Iluta, Ancuta Jurj, Grigore Gafencu, Sergiu Pasca, Andreea Terec, Patric Teodorescu, Cristina Selicean, Ciprian Jitaru, Maria Iordache, Catalin Constantinescu, Richard Feder, Raluca Munteanu, Delia Dima, Diana Gulei, Tudor Ciuleanu, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2021, in press. **impact factor: 4.486**.
53. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT T-CELL LEUKEMIA/LYMPHOMA – ROMANIAN EXPERIENCE. Alina D. Tanase, Andrei Colita, Oana G. Craciun, Lavinia Lipan, Zsofia Varady, Laura Stefan, Adela Ranate, Sergiu Pasca, Horia Bumbea, Mihaela Andreescu, Viola Popov, Alexandru Bardas, Daniel Coriu, Anca Roxana Lupu, **Ciprian Tomuleasa**, Anca Colita, Olivier Hermine. Journal of Clinical Medicine, 2020, in press. **impact factor: 4.674**.
54. DATABASE-GUIDED ANALYSIS FOR IMMUNOPHENOTYPIC DIAGNOSIS AND FOLLOW-UP OF ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES. Carmen-Mariana Aanei, Richard Veyrat-Masson, Cristina Selicean, Mirela Marian, Lauren Rigollet, Adrian Pavel Trifa, **Ciprian Tomuleasa**, Adrian Serban, Mohamad Cherry, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Denis Guyotat-Catafal. Frontiers in Oncology, 2021, in press. **impact factor: 4.448**.
55. TET2 RS1548483 NSP ASSOCIATING WITH SUSCEPTIBILITY TO MOLECULARLY ANNOTATED POLYCYTHEMIA VERA AND PRIMARY MYELOFIBROSIS. Diana Lighezan, Anca Bojan, Mihaela Iancu, Raluca Pop, Ștefana Gligor-Popa, Florin Tripon, Adriana Cosma, **Ciprian Tomuleasa**, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Ioana Ioniță, Ildikó Gaál, Simona Vișan, Andreea-Manuela Mirea, Radu Popp, Mira Florea, Cătălin Araniciu, Lucian Petrescu, Ioan Pop, Claudia Bănescu, Adrian Trifa. Journal of Personalized Medicine in press. **impact factor: 4.433**.
56. LONG NON-CODING RNAs IN MYELOID MALIGNANCIES. Alina-Andreea Zimta, **Ciprian Tomuleasa**, George Calin, Ioana Berindan-Neagoe, Frontiers in Oncology, 2019, in press. **impact factor: 4.416**.
57. KRAS/NRAF/BRAF MUTATIONS AS POTENTIAL TARGETS IN MULTIPLE MYELOMA. Sergiu Pasca, **Ciprian Tomuleasa**, Gabriel Ghiaur, Patric Teodorescu, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, Aaron Ciechanover, Hermann Einsele. Frontiers in Oncology, 2019, in press. **impact factor: 4.416**.
58. CURRENT THERAPEUTICS IN THE MANAGEMENT OF HEMOPHILIA – A CONSENSUS VIEW BY THE ROMANIAN SOCIETY OF HEMATOLOGY. Ionut Hotea, Melen Brinza, Cristina Blag, Alina-Andreea Zimta, Noemi Dirzu, Ioana Rus, Dragos Apostu, Horea Benea, Mirela Marian, Alexandru Mester, Sergiu Pasca, Sabina Ioana Iluta, Patric Teodorescu, Ciprian Jitaru, Mihnea Zdrenghea, Anca Bojan, Tunde Torok-Vistai, Radu Niculescu, Cristina Tarniceriu, Delia Dima, Margit Serban, **Ciprian Tomuleasa**, Daniel Coriu. Annals of Translational Medicine, 2021, in press. **impact factor: 4.421**.
59. EXTRAMEDULLARY HEMATOPOIESIS OF THE LIVER AND SPLEEN. Diana Cenariu, Sabina Iluta, Alina-Andreea Zimta, Bobe Petrushev, Liren Qian, Noemi Dirzu, **Ciprian Tomuleasa**, Horia Bumbea, Florin Zaharie. Journal of Clinical Medicine, 2021, in press, **impact factor: 4.241**.
60. SERS-BASED DNA METHYLATION PATTERN FOR THE POINT-OF-CARE DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY. INITIAL ASSESSMENT COMPARING REACTIVE LYMPH NODES, B-CELL LYMPHOMAS, T-CELL LYMPHOMAS AND METASTATIC MELANOMA. Andrei Stefancu, Vlad Moisoiu, Stefania D. Iancu, Minodora Desmirean, Bobe Petrushev, Ancuta Jurj, Liviuta Budisan, Bogdan Fetica, Andrei Roman, Gina Dobie, Cristina Turcas, Mihnea Zdrenghea, Patric Teodorescu, Sergiu Pasca, Doina Piciu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. Colloids and Surfaces B: Biointerfaces, in press. **impact factor: 4.389**.
61. GOLD NANOPARTICLES ENHANCE THE EFFECT OF TYROSIN KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY. Bobe Petrushev, Sanda Boca, Timea Simon, Cristian Berce, Ioana Frinc, Delia Dima, Sonia Selicean, Grigore-Aristide Gafencu, Alina Tanase, Mihnea Zdrenghea, Adrian Florea, Sorina Suarasan, Liana

- Dima, Raluca Stanciu, Ancuta Jurj, Anca Buzoianu, Andrei Cucuianu, Simion Astilean, Alexandru Irimie, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. International Journal of Nanomedicine, 2016; 11:641-60. **impact factor: 4.383.**
62. IN VIVO ASSESSMENT OF BONE MARROW TOXICITY FOR GOLD NANOPARTICLE-BASED BIOCONJUGATES IN CRL:CD1(ICR) MICE. Cristian Berce, Ciprian Lucan, Bobe Petrushev, Sanda Boca, Mirela Miclean, Orsolya Sarpataki, Simion Astilean, Anca Buzoianu, **Ciprian Tomuleasa**, Anca Bojan. International Journal of Nanomedicine, 2016; 11:4261-73. **impact factor: 4.383.**
 63. STRUCTURAL CHANGES OF RESIN BASED COMPOSITES IN SALIVA OF PATIENTS WITH LEUKEMIA BEFORE STARTING CHEMOTHERAPEUTIC REGIMEN. Alexandru Mester, Marioara Moldovan, Stanca Cuc, Ioan Petean, **Ciprian Tomuleasa**, Andra Piciu, Cristian Dinu *, Simion Bran, Florin Onisor. Polymers, 2022, in press. **impact factor: 4.329.**
 64. IBRUTINIB MONOTHERAPY AS BRIDGE-TO-TRANSPLANT FOR RELAPSED/REFRACTORY PRIMARY OCULO-CEREBRAL LYMPHOMAS. ROMANIAN EXPERIENCE. Dalma Deak-Mihaly, Sabina Iluta, Sergiu Pasca, Ciprian Jitaru, Andrei Roman, Alexandra Andries, Monica Padurariu-Covit, Anca Vasilache, Anca Bojan, Angela Dascalescu, Ion Antohe, Anca Colita, Andrei Colita, Delia Dima, Alina Tanase, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2021, in press. **impact factor: 4.241.**
 65. THE PREDICTIVE ROLE OF MODIFIED EARLY WARNING SCORES IN 174 HEMATOLOGICAL PATIENTS AT RISK FOR TRANSFER TO THE INTENSIVE CARE UNIT. Catalin Constantinescu, Sergiu Pasca, Sabina Iluta, Grigore Gafencu, Maria Santa, Ciprian Jitaru, Patric Teodorescu, Delia Dima, Mihnea Zdrengeha, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2021, in press, **impact factor: 4.241.**
 66. EDITORIAL: NOVEL DRUGS TARGETING THE MICROENVIRONMENT AND THE EPIGENETIC CHANGES IN HEMATOPOIETIC MALIGNANCIES. Diana Gulei, **Ciprian Tomuleasa**, Liren Qian, Cristina Bagacean, Carlo M. Croce, Gabriel Ghiaur. Frontiers in Pharmacology 2020, in press. **impact factor: 4.225.**
 67. NANOPHARMACOLOGY IN TRANSLATIONAL HEMATOLOGY AND ONCOLOGY. **Ciprian Tomuleasa**, Cornelia Braicu, Alexandra Irimie, Lucian Craciun, Ioana Berindan-Neagoe. Int J Nanomedicine. 2014;9:3465-79. **impact factor: 4.195.**
 68. REVERSING CHEMORESISTANCE OF MALIGNANT GLIOMAS STEM CELLS USING GOLD NANOPARTICLES. Anamaria Orza, Olga Soritau, **Ciprian Tomuleasa**, Liliana Olenic, Adrian Florea, Ovidiu Pana, Ioan Bratu, Eموke Pall, Stefan Florian, Dan Casciano, Alexandru S. Biris. International Journal of Nanomedicine 2013, 8:1-14. **impact factor: 4.195**
 69. SORAFENIB FOR THE TREATMENT OF SOLID MALIGNANCIES. WHAT ABOUT THE CANCER MICROENVIRONMENT? **Tomuleasa C**, Cucuianu A, Aldea M, Berindan-Neagoe I. International Journal of Nanomedicine. 2013; 8:4043-4. **impact factor: 4.195.**
 70. MRI-BASED IDENTIFICATION OF UNDIFFERENTIATED CELLS. LOOKING AT THE TWO FACES OF JANUS. **Tomuleasa C**, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. International Journal of Nanomedicine 2014, 9:865-6. **impact factor: 4.195.**
 71. DOSE INTENSITY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR PEDIATRIC CNS MALIGNANCIES. Seiji Kojima, Andrei Cucuianu, Yoshiyuki Takahashi, Ioana Berindan-Neagoe, Ioan Stefan Florian, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2014, 9:3247-8. **impact factor: 4.195.**
 72. SMALL MOLECULES AGAINST B-RAF (BRAF) VAL600GLU (V600E) SINGLE MUTATION. Florin Zaharie, Roxana Cojocneanu-Petric R, Mihai Muresan, Ioana Frinc, Delia Dima, Bobe Petrushev, Alina Tanase, Cristian Berce, Mariana Chitic, Ioana Berindan-Neagoe, Valentina Pileczki, Alexandru Irimie, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2015, 9:3247-8. **impact factor: 4.195.**
 73. THE MALIGNANT ROLE OF EXOSOMES AS NANOCARRIERS OF RARE RNA SPECIES. Alina-Andreea Zimta, Olafur Eysteinn Sigurjonsson, Diana, **Ciprian Tomuleasa**. International Journal of Molecular Sciences, 2020, in press. **impact factor: 4.183.**
 74. FIBROBLAST DYNAMICS AS AN IN VITRO SCREENING PLATFORM FOR ANTI-FIBROTIC DRUGS IN PRIMARY MYELOFIBROSIS. **Ciprian Tomuleasa**, Sonia Selicean, Grigore Gafencu, Bobe Petrushev, Daiana Temian, Laura Pop, Cristian Berce, Ancuta Jurj, Adrian Trifa, Ana Maria Rosu, Sergiu Pasca, Lorand Magdo, Delia

- Dima, Mihnea Zdrenghea, Ioana Frinc, Anca Bojan, Alina Tanase, Ioana Berindan-Neagoe, Gabriel Ghiaur, Stefan Ciurea. *Journal of Cellular Physiology* 2018, in press. **impact factor: 4.155.**
75. DAY 15 AND DAY 33 MINIMAL RESIDUAL DISEASE ASSESSMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ACCORDING TO THE BFM ALL IC 2009 PROTOCOL. SINGLE-CENTER EXPERIENCE OF 133 CASES. Letitia Elena Radu, Sergiu Pasca, Andrei Colita, **Ciprian Tomuleasa**, Codruta Popa, Catalin Serban, Anca Gheorghe, Andreea Serbanica, Cristina Jercan, Andra Marcu, Ana Bica, Patric Teodorescu, Catalin Constantinescu, Bobe Petrushev, Minodora Asan, Cerasela Jardan, Mihaela Dragomir, Alina Tanase, Anca Colita. *Frontiers in Oncology*, 2020, in press, **impact factor: 4.137.**
 76. SERS-BASED ASSESSMENT OF MRD IN ACUTE PROMYELOCYTIC LEUKEMIA? Cristina Turcas, Vlad Moisoiu, Andrei Stefancu, Ancuta Jurj, Stefania D. Iancu, Patric Teodorescu, Sergiu Pasca, Anca Bojan, Adrian Trifa, Sabina Iluta, Andreea Zimta, Bobe Petrushev, Mihnea Zdrenghea, Horia Bumbea, Daniel Coriu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. *Frontiers in Oncology*, in press. **impact factor: 4.137.**
 77. CD19-TARGETED, RAMAN-TAGGED GOLD NANOURCHINS AS THERANOSTIC AGENTS AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA. Andra-Sorina Tatar, Ancuta Jurj, **Ciprian Tomuleasa**, Adrian Florea, Ioana Berindan-Neagoe, Dana Cialla-May, Juergen Popp, Simion Astilean, Sanda Boca. *Colloids and Surfaces B: Biointerfaces*, 2019, in press. **impact factor: 3.997.**
 78. THE NON-MUTATIONAL CAUSES OF HEMOPHILIA: NON-CODING RNAs AND ACQUIRED HEMOPHILIA. Alina-Andreea Zimta, Ionut Hotea, Melen Brinza, Cristina Blag, Sabina Iluta, Catalin Constantinescu, Atamyrat Bashimov, Elisabeth-Antonia Marchis-Hund, Alexandra Coudsy, Laetitia Muller-Mohnssen, Noemi Dirzu, Diana Gulei, Delia Dima, Margit Serban, Daniel Coriu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2021, **impact factor: 3.9**, in press.
 79. THE ROLE OF PATHOLOGY DEPARTMENT IN THE PRE-ANALYTICAL PHASE OF MOLECULAR ANALYSES. Sergiu Susman, Ioana Berindan-Neagoe, Bobe Petrushev, Radu Pirlog, Ioan-Stefan Florian, Carmen-Mihaela Mihu, Cristian Berce, Lucian Craciun, Ravnit Grewal, **Ciprian Tomuleasa**, *Cancer Management and Research*, in press, **impact factor: 3.851.**
 80. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
 81. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
 82. A NARRATIVE VIEW OF CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LEUKEMIAS. Dalma Deak, Nicolae Gorcea-Andronic, Valentina Sas, Patric Teodorescu, Sabina Iluta, Sergiu Pasca, Ionut Hotea, Cristina Turcas, Simona Galdean, Jakob Steinheber, Ioana Rus, Sebastian Rauch, Raluca Munteanu, Ancuta Jurj, Bobe Petrushev, Cristina Selicean, Mirela Marian, Olga Soritau, Alexandra Andries, Andrei Roman, Delia Dima, Alina Tanase, **Ciprian Tomuleasa**. *Annals of Translational Medicine*, 2021, in press, **impact factor: 3.689.**
 83. B CELLS VERSUS T CELLS IN THE TUMOR MICROENVIRONMENT OF MALIGNANT LYMPHOMAS. ARE THE LYMPHOCYTES PLAYING THE ROLES OF MUHAMMAD ALI VERSUS GEROGGE FOREMAN IN ZAIRE 1974? Minodora Desmirean, Sebastian Rauch, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Patric Teodorescu, Cristian Berce, Andreea-Alina Zimta, Cristina Turcas, Irene Paris, Jakob Steinheber, Cedric Richlitzki, Bogdan Fetica, Delia Dima, Alina Tanase, Bobe Petrushev, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2020, in press. **impact factor: 3.5.**
 84. OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR LYMPHOMA WITH MELPHALAN-BASED CONDITIONING. Jonathan E. Brammer, Issa Khouri, Sameh Gaballa, Paolo Anderlini, Sairah Ahmed, Celina Ledesma, **Ciprian Tomuleasa**, Chitra Hosing, Richard E. Champlin, Stefan O. Ciurea. *Biology of Blood and Marrow Transplantation* 2015, 2016; 22(3):493-8. **impact factor: 3.404.**
 85. CUTANEOUS WOUND HEALING USING POLYMERIC SURGICAL DRESSINGS BASED ON CHITOSAN, SODIUM HYALURONATE AND RESVERATROL. Cristian Berce, Isabella Rigo, Bobe Petrushev, Lucia Tefas, Gheorghe Ungureanu, Mihai-Stefan Muresan, Olga Soritau, Cornel Catoi, Alexandru Irimie, **Ciprian Tomuleasa**. *Colloids and Surfaces B. Biointerfaces*, in press 2017. **impact factor: 3.387.**

86. CASTLEMAN'S DISEASE IN THE HIV-ENDEMIC SETTING. Esam-Rajab Mahroug, Candice Sher-Locketz, Minodora-Silvia Desmirean, Emmanuel-Akinola Abayomi, **Ciprian Tomuleasa**, Ravnit Grewal. *Cancer Management and Research*, 2018, in press. **impact factor: 3.351.**
87. SYSTEMIC SIDE-EFFECTS OF FDA AND/OR EMA-APPROVED TARGETED THERAPIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES. Catalin Constantinescu, Sergiu Pasca, Alina-Andreea Zimta, Tiberiu Tat, Ioana Rus, Patric Teodorescu, Sabina Iluta, Alina Tanase, Olafur Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2020, in press. **impact factor: 3.303.**
88. REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY. Miyakawa Yoshitaka, Sanford David, Tomuleasa Ciprian, Hsiao Hui Hua, Enjeti Anoop, Gimenez Conca Alberto, Bernal del Castillo Teresa, Girshova Larisa, Martelli Maria, Guvenc Birol, Delgado Alexander, Duan Yinghui, Llamas Cynthia D, Lee Je-Hwan. *Leukemia and Lymphoma*, 2021, in press. **impact factor: 3.28.**
89. ANTIPROLIFERATIVE EFFECT OF NOVEL PLATINUM(II) AND PALLADIUM(II) COMPLEXES ON HEPATIC TUMOR STEM CELLS IN VITRO. Natalia Miklášova, Eva Fischer-Fodor, Peter Lönnecke, **Ciprian Ionut Tomuleasa**, Piroška Virag, Maria Perde-Schrepler, Roman Mikláš, Luminita Silaghi-Dumitrescu, Evamarie Hey-Hawkins. *European Journal of Medicinal Chemistry* 2012, 49C:41-47. **impact factor: 3.27**
90. SYNTHESIS AND *IN VITRO* ANTIPROLIFERATIVE ACTIVITY OF NEW THIAZOLO [4,5-B]PHENOTHIAZINE AGAINST HUMAN LEUKEMIA. Balasz Brem, Emese Gal, Luiza Gaina, Castelia Cristea, Luminita Silaghi-Dumitrescu, Eva Fischer-Fodor, **Ciprian Ionut Tomuleasa**, Adriana Grozav, Valentin Zaharia, Lorena Filip. *International Journal of Molecular Sciences*, in press. **impact factor 3.257.**
91. MESENCHYMAL STEM CELLS IN MYELOPROLIFERATIVE DISORDERS – FOCUS ON PRIMARY MYELOFIBROSIS. Sonia Selicean, **Ciprian Tomuleasa**, Ravnit Grewal, Graca Almeida-Porada, Ioana Berindan-Neagoe. *Leukemia and Lymphoma*, 2018, accepted for publication. **impact factor: 3.093.**
92. LABEL-FREE SERS ON BLOOD GENOMICS DNA. TOWARDS THE DETECTION OF ACUTE MYELOID LEUKEMIA IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION. Vlad Moisoiu, Andrei Stefanu, Stefania Iancu, Tudor Moisoiu, Luminita Loga, Lucia Dican, Cristian Alecsa, Imre Boros, Anca Jurj, Delia Dima, Cristina Bagacean, Romulus Tetean, Emil Burzo, **Ciprian Tomuleasa**, Florin Elec, Nicolae Leopold. *Analytical and Bioanalytical Chemistry*, 2019, in press. **impact factor: 3.307.**
93. MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER. Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, **Ciprian Tomuleasa**, Irinel Popescu, Sorin Alexandrescu, Delia Dima, Mihaela Chivu-Economescu, Elizabeth A. Montgomery, Michael Torbenson, Christine Vazquez, Stephen J Meltzer, Florin M Selaru. *Digestive and Liver Diseases*, 2012, 44(7):589-596. **impact factor: 3.05**
94. Hsiao HH, Enciso Olivera LJ, Ito T, Bui C, Sanford D, Duan Y, Garbayo Guijarro MB, Martelli M, Bernal del Castillo T, Girshova L, Delgado A, Enjeti A, Tomuleasa C, Guvenc B, Llamas C, Lee JH, Gimenez Conca A. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. *European Journal of Haematology* 2022, in press. **impact factor: 2.997.**
95. THE NEW ERA OF NANOTECHNOLOGY, AN ALTERNATIVE TO CHANGE CANCER TREATMENT. Ancuta Jurj, Laura Pop, Cornelia Braicu, **Ciprian Tomuleasa**, Claudia Gherman, Ioana Berindan-Neagoe. *Drug Design, Development and Therapy*, in press. **impact factor: 2.881.**
96. MICRORNAS FOR THE DIAGNOSIS OF GRAFT VERSUS HOST DISEASE. **Ciprian Tomuleasa**, Shigeo Fujii, Andrei Cucuianu, Markus Kapp, Sonia Selicean, Alina Tanase, Delia Dima, Bobe Petrushev, Valentina Pileczki, Ioana Berindan-Neagoe, Alexandru Irimie, Hermann Einsele. *Annals of Hematology* 2015, 94(7):1081-92. **impact factor: 2.866.**
97. DESIGN OF FLT3 INHIBITOR GOLD NANOPARTICLE CONJUGATES AS POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. Timea Simon, **Ciprian Tomuleasa**, Anca Bojan, Ioana Berindan-Neagoe, Sanda Boca, Simion Astilean. *Nanoscale Research Letters* 2015, 2015; 10(1):466. **impact factor: 2.78.**

98. CLINICOPATHOLOGICAL ANALYSIS OF A CASE SERIES OF PERIPHERAL T-CELL LYMPHOMAS, NOT OTHERWISE SPECIFIED, OF LYMPHOEPITELIOID VARIANT (LENNER'S LYMPHOMA). A CENTRAL EUROPEAN SINGLE-CENTER STUDY. Grigore-Aristide Gafencu, Sonia Selicean, Bobe Petrushev, Andrei Cucuianu, Delia Dima, Ioana Frinc, Alexandru Irimie, Rares Buiga, Valentina Pileczki, Ioana Berindan-Neagoe, Cristian Berce, **Ciprian Tomuleasa**. *Human Pathology*, 2016; 53:192-4. **impact factor: 2.769**.
99. INFLAMMATION, TUMORAL MARKERS AND INTERLEUKIN-17, -10 AND -6 PROFILES IN PANCREATIC ADENOCARCINOMA AND CHRONIC PANCREATITIS. Alina Tantau, Daniel-Corneliu Leucuta, Marcel Tantau, Emil Botan, Roxana Zaharie, **Ionut-Ciprian Tomuleasa**. *Digestive Diseases and Sciences*, 2020, in press. **impact factor: 2.751**.
100. THE ROLE OF TGF- β IN TISSUE MICROENVIRONMENT: A POTENTIAL NEW THERAPEUTIC APPROACH IN HCC TREATMENT. Bhavna Rani, Yuan Cao, Andrea Malfettone, **Ciprian Tomuleasa**, Isabel Fabregat, Gianluigi Giannelli. *World Journal of Gastroenterology* 2014, 20(15):4128-4140. **impact factor: 2.547**.
101. REPOSITIONING METFORMIN IN CANCER: GENETICS, DRUG TARGETS AND NEW WAYS OF DELIVERY. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Gabriel Kacso, Ioan-Stefan Florian, Carmen Crivii. *Tumour Biology*. 2014; 35(6):5101-10. **impact factor: 2.518**.
102. THE INFLUENCE OF METHYLATING MUTATIONS ON CHOOSING ACUTE MYELOID LEUKEMIA CHEMOTHERAPY. PRELIMINARY ANALYSIS ON 58 PATIENTS. Sergiu Pasca, Cristina Turcas, Ancuta Jurj, Patric Teodorescu, Sabina Iluta, Ionut Hotea, Cristina Selicean, Bogdan Fetica, Bobe Petrushev, Vlad Moisoiu, Alina-Andreea Zimta, Valentina Sas, Catalin Constantinescu, Mihnea Zdrengeha, Delia Dima, **Ciprian Tomuleasa**. *Diagnostics*, 2020, in press. **impact factor: 2.489**.
103. CLINICAL REMISSION FOR AN ELDERLY PATIENT WITH A MASSIVE PRIMARY CUTANEOUS PERIPHERAL T-CELL LYMPHOMA-NOS OF THE EYE, FOLLOWING COMBINATION CHEMOTHERAPY WITH ETOPOSIDE PLUS COP. Sabina Iluta, Dragos-Alexandru Termure, Bobe Petrushev, Mindra-Eugenia Badea, Madalina Moldovan-Lazar, Manuela Lenghel, Csaba Csutak, Andrei Roman, Sergiu Pasca, Cedric Richlitzki, Sebastian Rauch, Delia Dima, **Ciprian Tomuleasa**, Rares-Calin Roman. *Diagnostics*, 2020, in press. **impact factor: 2.489**.
104. GELATIN COATED GOLD NANOPARTICLES AS CARRIERS OF FLT3 INHIBITOR DRUGS FOR ACUTE MYELOID LEUKEMIA TREATMENT. Sorina Suarasan, Timea Simon, Sanda Boca, **Ciprian Tomuleasa**, Simion Astilean. *Chemical Biology and Drug Design*, 2016; 87(6):927-35. **impact factor: 2.485**.
105. USE OF FLOW CYTOMETRY IN THE PHENOTYPIC AND DIAGNOSIS OF HODGKIN'S LYMPHOMA. Ravnit Grewal, Manogari Chetty, Emmanuel Akinola Abayomi, **Ciprian Tomuleasa**, Jonathan R. Fromm. *Cytometry Part B. Clinical Cytometry*, 2018, in press. **impact factor: 2.474**.
106. PERIODONTAL DISEASE AND VON WILLEBRAND DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Alexandru Mester, Leonardo Mancini, Enrico Marchetti, Mihaela Baciut, Simion Bran, Ondine Lucaciu, Grigore Baciut, **Ciprian Tomuleasa**, Sergiu Pasca, Andra Piciu, Andrada Voina-Tonea, Horia Opris, Daiana Antoaneta Prodan, Florin Onişor. *Applied Sciences*, 2021, in press. **impact factor: 2.474**.
107. NOVEL PALADIUM (III) COMPLEXES INFLUENCE PROMININ-1/CD133 EXPRESSION AND STEM CELL FACTOR RELEASE IN TUMOR CELLS. Natalia Miklášova, Eva Fischer-Fodor, Roman Mikláš, Mihai Cenariu, Piroška Virag, **Ciprian I Tomuleasa**, Corina Tatomir, Ioana Berindan-Neagoe, Ferdinand Devinsky. *Molecules (Basel)*, 2017; 22(4). pii: E561. **impact factor 2.465**.
108. METFORMIN, ARSENIC TRIOXIDE, OLANZAPINE AND BETA-BLOCKERS AS NEW HORIZONS FOR GLIOBLASTOMA THERAPY. HAS TIME COME FOR CLINICAL TRIALS? Marco Carmignani, Mihaela Aldea, Olga Soritau, Anna Rita Volpe, Alexandru Irimie, Ioan-Stefan Florian, **Ciprian Tomuleasa**, Bobe Petrushev, Adriana Baritchii, Gianina Crisan, Guido Valle. *Journal of biological regulators and homeostatic agents* 2014, 28(1):1-15. **impact factor: 2.406**.
109. SEROPREVALENCE OF BARTONELLA SPECIES, COXIELLA BURNETII AND TOXOPLASMA GONDII AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A PILOT STUDY IN ROMANIA. Chelsea J. Messinger, Eugen Gurzau, Ed Breitschwerdt, **Ciprian Tomuleasa**, Sally Trufan, Ricardo G. Maggi, Ioana Berindan-Neagoe, Peter Rabinowitz. *Zoonoses and Public Health* 2017, in press. **impact factor: 2.369**.

110. THE USE OF ROTATION TO FENTANYL IN CANCER-RELATED PAIN. Delia Dima, **Ciprian Tomuleasa**, Ioana Frinc, Sergiu Pasca, Lorand Magdo, Mihai Muresan, Ioana Berindan-Neagoe, Cosmin Lisencu, Alexandru Irimie, Mihnea Zdrenghea. *Journal of Pain Research*, 2017; 10:341-348. **impact factor: 2.363.**
111. JAK2 V617F ALLELE BURDEN CONTRIBUTED TO THE OCCURANCE OF MAJOR THROMBOSIS IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA. Adrian Trifa, Claudia Banescu, Cristian Voina, Stefana Popa, Tunde Torok-Vistai, Anca Bojan, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Simona Visan, **Ciprian Tomuleasa**, Bogdan Pop, Viola Popov, Mihaela Andreescu, Radu Popp. *Blood Cells, Molecules and Disease* 2018, in press. **impact factor: 2.331.**
112. ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA. RARE ASSOCIATION WITH CYTOPENIAS OF UNDETERMINED SIGNIFICANCE AND P210 AND P190 BCR-ABL TRANSCRIPTS. Delia Dima, Liana Oprita, Ana-Maria Rosu, Bobe Petrushev, Adrian Trifa, Cristina Selicean, Vlad Moisoiu, Ioana Rus, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *OncoTargets and Therapy*, in press. **impact factor: 2.311.**
113. BCR-ABL T315I MUTATION, A NEGATIVE PROGNOSTIC FACTOR FOR THE TERMINAL PHASE OF CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH FIRST AND SECOND LINE TYROSINE KINASE INHIBITORS, MIGHT BE AN INDICATOR OF ALLOGENEIC STEM CELL TRANSPLANTATION AS THE TREATMENT OF CHOICE. **Ciprian Tomuleasa**, Delia Dima, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe. *Leukemia and Lymphoma* 2015, 56(2):546-7. **impact factor: 2.301.**
114. BASIC KNOWLEDGE ON BCR-ABL1 POSITIVE EXTRACELLULAR VESICLES. Ancuta Jurj, Sergiu Pasca, Patric Teodorescu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *Biomarkers in Medicine*, 2020, in press, **impact factor: 2.268.**
115. IMPLICATION OF TET2 IN CAR-T CELL ACTIVITY AND TARGET'S RESPONSE TO CAR-T CELL THERAPY. LESSONS LEARNED FROM T-CELLS. Sergiu Pasca, Ancuta Jurj, Catalin Constantinescu, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *Critical Reviews in Immunology*, 2021, in press. **impact factor: 2.237.**
116. THE LAUREN CLASSIFICATION HIGHLIGHTS THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION IN CARCINOGENESIS: AN IMMUNOHISTOCHEMISTRY STUDY OF THE STAT3 AND ADHESION MOLECULES EXPRESSION. Sergiu Susman, Raphaelle Barnoud, Frederique Bibeau, Francesco Borini, Marc Pocard, **Ciprian Tomuleasa**, Jean-Christophe Sabourin. *Journal of Gastrointestinal and Liver Diseases* 2015, 24(1):77-83. **impact factor: 2.202.**
117. DO LYMPHOMAS HAVE AN AUTOIMMUNE BACKGROUND AND HOW CAN WE INCREASE THE SENSITIVITY OF THE DIAGNOSIS OF PRIMARY PANCREATIC LYMPHOMA WITH RELATIVELY SMALL SAMPLES ? **Ciprian Tomuleasa**, **Emmanuel Akin-Abayomi**, Delia Dima, Cristian Tefas, Alexandru Irimie, Bobe Petrushev, Ioana Frinc, Ravnit Grewal. *Journal of Gastrointestinal and Liver Diseases* 2015, 24(3):391-2. **impact factor: 2.202.**
118. EXOSOME-CARRIED MICRORNA-375 INHIBITS CANCER CELL PROGRESSION VIA BCL-2 BLOCKING IN COLON CANCER. Mihai-Stefan Muresan, Florin Zaharie, Bobe Petrushev, Cristian Berce, Grigore Gafencu, Sonia Selicean, Ancuta Jurj, Roxana Cojocneanu-Petric, Cosmin-Ioan Lisencu, Laura-Ancuta Pop, Valentina Pileczki, Dan Eniu, Mihai-Andrei Muresan, Roxana Zaharie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Alexandru Irimie. *Journal of Gastrointestinal and Liver Diseases* 2015, 2015; 24(4):435-43. **impact factor: 2.202.**
119. HENoch SCHONLEIN PURPURA AND CLOSTRIDIUM DIFFICILE INFECTION, A HEMATOLOGISTS' POINT OF VIEW. Delia Dima, **Ciprian Tomuleasa**, Mihnea Zdrenghea. *Journal of Gastrointestinal and Liver Diseases*, 2016; 25(3):411. **impact factor: 2.202.**
120. HOW TO DIAGNOSE AND TREAT A CANCER OF UNKNOWN PRIMARY SITE. **Ciprian Tomuleasa**, Mihai Stefan Muresan, Florin Zaharie, Laura Pop, Zsolt Fekete, Delia Dima, Ioana Frinc, Adrian Trifa, Cristian Berce, Ancuta Jurj, Ioana Berindan-Neagoe, Mihnea Zdrenghea, Tudor Ciuleanu. *Journal of Gastrointestinal and Liver Diseases*, 2017; 26(1):69-79. **impact factor: 2.202.**
121. ANTIPROLIFERATIVE AND APOPTOTIC IN VITRO EFFECTS OF LIDOCAINE ON HUMAN HEPATOCARCINOMA CELLS. Ancuta Jurj, **Ciprian Tomuleasa**, Tiberiu Tat, Ioana Berindan-Neagoe, Stefan V. Vesa, Daniela Ionescu. *Journal of Gastrointestinal and Liver Diseases*, 2017; 26(1):45-50. **impact factor: 2.202.**
122. NEXT GENERATION SEQUENCING-BASED CHARACTERIZATION OF THE INVASION BY ANATOMICAL CONTIGUITY IN A PRIMARY OSSEOUS DIFFUSE LARGE B-CELL LYMPHOMA. Florin Zaharie, Laura-Ancuta

- Pop, Bobe Petrushev, Mihai-Stefan Muresan, Dan Eniu, Bogdan Fetica, Doina Piciu, Ioana Rus, Delia Dima, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *Histology and Histopathology*, 2018, in press. **impact factor: 2.025.**
123. MANAGEMENT OF RENAL EXTRASKELETAL CHONDROSARCOMA. Vitalie Gherman, **Ciprian Tomuleasa**, Catalina Bungardean, Dan Vasile Stanca, Victor Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman. *BMC Surgery* 2014, 2014; 14:107. **impact factor: 1.97.**
 124. CHRONIC GRANULAMATOUS DERMATOSIS AS A PRESENTING SIGN FOR CUTANEOUS T-CELL LYMPHOMAS. Andrei Cucuianu, Bobe Petrushev, Doinita Crisan, Rares Buiga, Ana Maria Rosu, Delia Dima, **Ciprian Tomuleasa**. *European Journal of Dermatology* 2015, 25(2):210. **impact factor: 1.92.**
 125. GOLD NANOPARTICLES CONJUGATED WITH CISPLATIN/ DOXORUBICINE/ CAPECITABINE LOWER THE CHEMORESISTANCE OF HEPATOCELLULAR CARCINOMA-DERIVED CANCER CELLS. **Ciprian Tomuleasa**, Olga Soritău, Anamaria Orza, Mircea Ducea, Bobe Petrushev, Ofelia Mosteanu, Sergiu Susman, Adrian Florea, Eموke Pall, Mihaela Aldea, Gabriel Kacso, Victor Cristea, Ioana Berindan-Neagoe, Alexandru Irimie. *Journal of Gastrointestinal and Liver Diseases* 2012, 21(2):187-196. **impact factor: 1.81**
 126. ISOLATION AND CHARACTERIZATION OF HEPATIC CANCER CELLS WITH STEM LIKE PROPERTIES FROM HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Soritău, Dan Rus Ciucă, Teodora Pop, Daniela Todea, Ofelia Moșteanu, Bogdan Pinteau, Vasile Foris, Sergiu Sușman, Gabriel Kacsó, Alexandru Irimie, *Journal of Gastrointestinal and Liver Diseases*, 2010; 19(1):61-67. **impact factor: 1.81**
 127. ALDH AS A TUMOR MARKER FOR PANCREATIC CANCER. **Ciprian Tomuleasa**, Ofelia Mosteanu, Sergiu Susman, Victor Cristea. *Journal of Gastrointestinal and Liver Diseases* 2011, 20(4):443-446. **impact factor: 1.81**
 128. PARASITAEMIA AND HEMATOLOGICAL ALTERATIONS IN MALARIA-AFFECTED REFUGEES IN SOUTH AFRICA. Nonzwakazi Pretty Ntombela, Joyce Mahlako Tsoka-Gwegweni, Uchenna Okafor, Andrei Bibirigea, Alexandru Irimie, **Ciprian Tomuleasa**. *South African Medical Journal*, 2015, in press. **impact factor: 1.712**
 129. COMPARISON OF PERIPHERAL BLOOD STEM CELL MOBILIZATION WITH FILGRATIM VERSUS PEGFILGRASTIM IN LYMPHOMA PATIENTS – SINGLE CENTER EXPERIENCE. Lavinia Lipan, Andrei Colita, Laura Stefan, Carmen Calugaroiu, Catalin Serban, **Ciprian Tomuleasa**, Sergiu Pasca, Anca Colita, Alina Tanase. *Journal of the Balkan Union of Oncology* 2021; 26(3): 1080-1087. **impact factor: 1.695.**
 130. PROSPECTIVE INVESTIGATION OF PAIN ASSOCIATED WITH ULTRASOUND AND COMPUTED TOMOGRAPHY-GUIDED PERCUTANEOUS BIOPSIES IN ONCOLOGICAL PATIENTS. Andrei Roman, Federica Palego, Patriciu Achimas-Cadariu, Catalin Vlad, Alexandra Andries, **Ciprian Tomuleasa**, Vlad Alexandru Gata, Roxana Pintican, Patricia Maria Rada, Diana Feier. *Medical Ultrasonography*, 2020, in press. **impact factor: 1.674.**
 131. SORAFENIB FOR ADVANCED STAGE HEPATOCELLULAR CARCINOMA. **Ciprian Tomuleasa**, Victor Cristea, Alexandru Irimie. *European Journal of Gastroenterology and Hepatology*, 2012, 24(3):346-347. **impact factor: 1.66**
 132. BASELINE CHARACTERISTICS OF A NATIONWIDE COHORT OF PEDIATRIC PATIENTS WITH ACUTE LEUKEMIAS OF DOWN SYNDROME. Valentina Sas, Cristina Blag, Sergiu Pasca, Gheorghe Popa, Mirela Marian, Cristina Schnell, Daniela Voda, Smaranda-Teodora Arghirescu, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Cristina Selicean, Anca Bojan, Mihnea Zdrengeha, Margit Serban, Delia Dima, Gabriela Zaharie, Anca Colita, Sorin Man, **Ciprian Tomuleasa**. *Journal of the Balkan Union of Oncology*, 2020, in press, **impact factor: 1.6.**
 133. MATRIX-METALLOPROTEINASE-2 PREDICTS ARTERIOVENOUS FISTULA FAILURE IN HAEMODIALYSIS PATIENTS. Dacian Tirinescu, **Ciprian Tomuleasa**, Laura Pop, Dan Vladutiu, Crina Rusu, Dana Moldovan, Alina Potra, Ina Kacso. *Therapeutic Apheresis and Dialysis*, 2017, in press, **impact factor: 1.529.**
 134. TOPICAL CORTICOSTEROIDS, A VIABLE SOLUTION FOR ORAL GRAFT VERSUS HOST DISEASE? A SYSTEMATIC INSIGHT ON RANDOMIZED CLINICAL TRIALS. Arin Sava, Andra Piciu, Sergiu Pasca, Alexandru Mester, **Ciprian Tomuleasa**. *Medicina (Kaunas)*, 2020, in press. **impact factor: 1.5.**
 135. DNMT3A R882 AND TET2/IDH1/2 MUTATIONS IMPACT BLAST CELL DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA BUT NOT RESPONSE TO HYPOMETHYLATING AGENTS. Sergiu Pasca, Ancuta Jurj, **Ciprian Tomuleasa**, Mihnea Zdrengeha, *Medicina*, **impact factor: 1.2.** in press, 2020.

136. GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Sanda Boca, Ciprian Lucan, Ioana Frinc, Bobe Petrushev, Timea Simon, Cristian Berce, Grigore-Aristide Gafencu, Delia Dima, Alina Tanase, Sonia Selicean, Valentina Pileczki, Laura Pop, Adrian Florea, Alexandru Irimie, Simion Astilean, Anca Bojan, Ioana Berindan-Neagoe, Mihnea Zdrenghia, **Ciprian Tomuleasa**. Farmacia 2016, in pres **impact factor: 1.162**.
137. TRANSTHORACIC ULTRASONOGRAPHY FOR THE FOLLOW-UP OF A CHRONIC LYMPHOCYTIC LEUKEMIA CHEMOTHERAPY-IMMUNOCOMPROMISED PATIENT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION. CASE REPORT. Ioana Frinc, Delia Dima, Mariana Chitic, Cristian Berce, Ioana Berindan-Neagoe, Tiberiu Tat, Alina Tanase, **Ciprian Tomuleasa**, Anca Bojan. Medical Ultrasonography, in press. **impact factor 1.167**.
138. A SYSTEMATIC APPROACH ON THE FREQUENCY OF LEFT LIP/PALATE IN PEDIATRIC PATIENTS WITH LEUKEMIA. Daiana Antoaneta Prodan, Simion Bran, Cristian Dinu, Grigore Baciut, **Ciprian Tomuleasa**, Andra Piciu, Alexandru Mester, Mihaela Baciut. Journal of Stomatology, Oral and Maxillofacial Surgery 2020, in press. **impact factor: 1.152**.
139. PARP INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY: HOW A SYNTHETIC LETHALITY APPROACH CAN BE A VALID THERAPEUTIC ALTERNATIVE. Grigore Gafencu, **Ciprian Tomuleasa**, Gabriel Ghiur. Medical Hypotheses, in press, **impact factor :1.136**.
140. REDISTRIBUTION OF IRON TOWARDS DEPOSITS IN ERYTHROBLASTOPENIC ANEMIA AS A CONSEQUENCE OF DECREASED ERYTHROFERRONE PRODUCTION. Andrei Cucuianu, Mariana Patiu, Adrian P. Trifa, **Ciprian Tomuleasa**, Delia Dima. Medical Hypotheses 2014, 83(5):530-2. **impact factor: 1.054**.
141. RUXOLITINIB CONJUGATED WITH GOLD NANOPARTICLES, USED FOR TOPICAL ADMINISTRATION. AN ALTERNATIVE FOR TREATING ALOPECIA ? Sanda Boca-Farcu, Cristian Berce, Bobe Petrushev, Ancuta Jurj, Laura Pop, Grigore-Aristide Gafencu, Sonia Selicean, Vlad Moisoiu, Daiana Temian, Wilhelm-Thomas Micu, Simion Astilean, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Medical Hypotheses, in press. **impact factor: 1.03**.
142. HAPLOIDENTICAL DONORS: CAN FASTER TRANSPLANTATION BE LIFE-SAVING FOR PATIENTS WITH ADVANCED DISEASE ? Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Acta Haematologica 2015, 2016;135(4):211-6.. **impact factor: 0.994**
143. THE IMPORTANCE OF MICRO-RNAS IN THE STROMAL-BREAST CANCER CELL INTERPLAY. Sergiu Susman, **Ciprian Tomuleasa**, Zsolt Fekete, Brunella Pilato, Alexandru Irimie, Ioana Berindan-Neagoe. Cancer Biomarkers. 2014;14(2-3):137-44. **impact factor: 0.972**
144. HEMATOLOGY PATIENTS INFECTED WITH SARS-CoV-2 VIRUS, PRE-TREATED WITH ECULIZUMAB OR SILTUXIMAB, DEVELOP OLIGOSYMPTOMATIC DISEASE. Sabina Iluta, Sergiu Pasca, Delia Dima, Gabriela Mester, Laura Urian, Anca Bojan, Mihnea Zdrenghia, Adrian Trifa, Ovidiu Balacescu, **Ciprian Tomuleasa**. European Journal of Hospital Pharmacy, 2021, in press. **impact factor: 0.892**.
145. PARANEOPLASTIC SYNDROMES WITH CONNECTIVE TISSUE INVOLVEMENT. IT'S NOT ALWAYS LUPUS ! T Timis, C Berce, A Duarte-Garcia, B Petrushev, V Cristea, **C Tomuleasa**. Journal of the Balkan Union of Oncology 2012, 17:417-421. **impact factor: 0.76**
146. MESENCHYMAL STEM CELL IRRADIATION IN CULTURE ENGAGES DIFFERENTIAL EFFECT OF HYPERFRACTIONATED RADIOTHERAPY FOR HEAD AND NECK CANCERS, **C Tomuleasa**, V Foris, O Sorițău, T Dicu, E Páll, I Brie, G Kacsó, Journal of Balkanic Union of Oncology, 2010; 15(2):348-356. **impact factor: 0.76**.
147. FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME DERIVED CANCER STEM CELLS, **C Tomuleasa**, O Sorițău, D Rus Ciucă, H Ioani, S Sușman, M Petrescu, T Timis, D Cernea, G Kacsó, A Irimie, IS Florian, Journal of Balkan Union of Oncology, 2010; 15(3):583-591. **impact factor: 0.76**
148. METFORMIN PLUS TEMOZOLOMIDE-BASED CHEMOTHERAPY AS ADJUVANT TREATMENT FOR WHO GRADE III AND IV MALIGNANT GLIOMAS. O Soritau, **C Tomuleasa**, M Aldea, B Petrushev, S Susman, D

- Gheban, H Ioani, A Cocis, A Irimie, G Kacso, IS Florian. Journal of the Balkan Union of Oncology, 2011, 16:282-289. **impact factor: 0.76**
149. ANTIDIABETIC PHARMACOLOGY, A LINK BETWEEN METABOLIC SYNDROME AND NEURO-ONCOLOGY? M Aldea, **C Tomuleasa**, B Petrushev, S Susman, G Kacso, A Irimie, IS Florian, O Soritau. Journal of the Balkan Union of Oncology, 2011, 16:409-413. **impact factor: 0.76**
150. CANCER STEM CELLS AND MALIGNANT GLIOMAS. FROM PATHOPHYSIOLOGY TO TARGETED MOLECULAR THERAPY, IS Florian, **C Tomuleasa**, O Soritau, T Timis, G Kacso, A Irimie. Journal of the Balkan Union of Oncology, 2011, 16:16-23. **impact factor: 0.76**
151. ARSENIC TRIOXIDE SENSITIZES CANCER STEM CELLS TO CHEMORADIOTHERAPY – A NEW APPROACH IN THE TREATMENT OF INOPERABLE GLIOBLASTOMA MULTIFORME, **C Tomuleasa**, O Soritau, G Kacso, E Fischer-Fodor, A Cocis, H Ioani, M Petrescu, T Timis, D Cernea, P Virag, A Irimie, IS Florian, Journal of the Balkan Union of Oncology, 2010, 15:758-762. **impact factor: 0.76**
152. THE COLORECTAL CANCER STEM-LIKE CELL HYPOTHESIS. A PATHOLOGIST'S POINT OF VIEW. S Susman, **C Tomuleasa**, O Soritau, D Rus-Ciuca, J-C Sabourin, F Bibeau, A Irimie, R Buiga. Journal of the Balkan Union of Oncology, 2012, 17(2):230-236. **impact factor: 0.76**
153. THE ROLE OF DEPRESSION AND NEUROIMMUNE AXIS IN THE PROGNOSIS OF CANCER PATIENTS. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Carmen Crivii. Journal of the Balkan Union of Oncology 2014, 19(1):5-14. **impact factor: 0.76**
154. THE ANDROGEN RECEPTOR AS KEY PLAYER IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCERS. IMPLICATIONS FOR NEW TREATMENTS. Adina Nemes, **Ciprian Tomuleasa**, Gabriel Kacsó. Journal of the Balkan Union of Oncology 2014, 19(2): 357-364. **impact factor: 0.76**
155. MICRORNA-21 STIMULATES GASTRIC CANCER GROWTH AND INVASION BY INHIBITING THE TUMOR SUPPRESSOR EFFECTS OF PROGRAMMED CELL DEATH PROTEIN 4 AND PHOSPHATASE AND TENSIN HOMOLOG. Ling Li, Liya Zhou, Yuwen Li, Sanren Lin, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(1):228-236. **impact factor: 0.76**.
156. CANCER STEM –LIKE CELLS: THE DARK KNIGHTS OF CLINICAL HEMATOLOGY AND ONCOLOGY. Ioana Frinc, Mihai-Stefan Muresan, Florin Zaharie, Ljubomir Petrov, Cristian Berce, Alexandra Irimie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(2): 328-335. **impact factor: 0.76**.
157. METFORMIN PLUS SORAFENIB - AN ASSOCIATION THAT HIGHLY IMPACTS TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA STEM-LIKE CELLS. Mihaela Aldea, Bobe Petrushev, Olga Soritau, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Adriana Filip, Gabriela Chereches, Mihai Cenariu, Lucian Craciun, Corina Tatomir, Ioan-Stefan Florian, Carmen Crivii, Gabriel Kacso. Journal of the Balkan Union of Oncology 2014, 19(2): 502-511. **impact factor: 0.76**.
158. THE EFFECT OF ANAESTHETIC ON NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN (NGAL) LEVELS AFTER ROBOTIC SURGICAL ONCOLOGY. Orsolya Mihály, Attila-Zoltan Mihály, Vitalie Gherman, Florin Zaharie, Sorana Bolboacă, Ciprian Chira, Constantin Bodolea, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Coman, Daniela Ionescu. Journal of the Balkan Union of Oncology 2015, 20(1):317-24. **impact factor: 0.76**.
159. MICRORNAS IN LIVER MALIGNANCIES. BASIC SCIENCE APPLIED IN SURGERY. Mihai-Stefan Muresan, Florin Zaharie, Anca Bojan, Bobe Petrushev, Roxana Cojocneanu-Petric, Alexandru Irimie, Grigore Gafencu, Sonia Selicean, Cristian Tefas, Andreea Cioca, Cristian Berce, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Patriciu Achimas-Cadariu. Journal of the Balkan Union of Oncology 2015, 20(2):361-75. **impact factor: 0.76**.
160. ORAL SURGERY FOR COMBINED HAEMOPHILIA A AND B. THE DOS AND DON'TS IN A CLINICAL SCENARIO. Madalina Anca Lazar, Ovidiu Muresan, Calin Rares Roman, Delia Dima, Mihai Stefan Muresan, Gabriel Armencea, **Ciprian Tomuleasa**, Horatiu Rotaru. Ann Ital Chir, 2018; in press, **impact factor: 0.2**.
161. LAPAROSCOPIC SPLENECTOMY FOR HEREDITARY SPHEROCYTOSIS. Florin Zaharie, Mihai-Stefan Muresan, Cristina Blag, Roxana Zaharie, Claudiu Zdrehus, Mihnea Dragomir, Mihnea Zdreghea, Horia Bumbea, Alexandru Irimie, Delia Dima, **Ciprian Tomuleasa**, Gheorghe Popa. Ann Ital Chir, submitted for publication. **impact factor: 0.2**.
162. EFFECTS OF Co GAMMA-RAYS ON HUMAN OSTEOPROGENITOR CELLS, **C.I. Tomuleasa**, V. Foris, Olga Soritau, Emöke Páll, Eva Fischer-Fodor, V. Lung-Illes, Ioana Brie, Piroška Virág, Maria Perder-Schrepler, I.D. Postescu, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, Romanian Journal of Morphology and Embryology, 2009; 50(3):3-6.

163. PRIMUM NON NOCERE. IS STEM CELL RESEARCH READY FOR CLINICAL TRIALS ?, **Ciprian Tomuleasa**, Olga Sorițău, Sergiu Șuşman, Vasile Foris, Emöke Páll, Carmen Mihu, Journal of the European Medical Students Association, 2009; 4(4):33-38.
164. ARSENIC TRIOXIDE PLUS CISPLATIN/ INTERFERON α -2B/ DOXORUBICIN/ CAPECITABINE COMBINATION CHEMOTHERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorițău, Teodora Pop, Eva Fischer-Fodor, Ofelia Mosteanu, Bobe Petrushev, Sergiu Susman, Mihaela Aldea, Monica Acalovschi, Alexandru Irimie, Gabriel Kacsó. Hematology Oncology and Stem Cell Therapy, 2011, 4(2):60-66.
165. ENHANCED CHEMORESISTANCE AND TUMOUR SPHERE FORMATION AS A LABORATORY MODEL FOR PERITONEAL MICROMETASTASIS IN EPITHELIAL OVARIAN CANCER, Olga Sorițău, **CI Tomuleasa**, Emöke Páll, Piroska Virág, Eva Fischer-Fodor, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, G Kacsó, A Irimie, Romanian Journal of Morphology and Embryology, 2010, 51(2):3-6.
166. CELLULAR INTERACTIONS IN PROSTATE CANCER GENESIS AND DISSEMINATION. LOOKING BEYOND THE OBVIOUS, **C Tomuleasa**, G Kacsó, S Șuşman, Olga Sorițău, Carmen Mihu, A Irimie, Piroska Virág, Romanian Journal of Morphology and Embryology, 2010, 51(3):427-435.
167. PARANEOPLASTIC SYNDROMES AS KEY ELEMENTS OF DIFFERENTIAL DIAGNOSIS. Tanase Timis, Doru Tomesc, Bobe Petrushev, Claudiu Sas, Mihaela Aldea, **Ciprian Tomuleasa**. Journal of the European Medical Students Association, 2011, 6(1):7-12.
168. PLACENTAL STEM CELL DIFFERENTIATION INTO ISLETS OF LANGERHANS-LIKE GLUCAGON SECRETING CELLS. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, VI Pop, Carmen Mihaela Mihu. Romanian Journal of Morphology and Embryology, 2010, 51(4):733-738.
169. PANCREATIC EXOCRINE ADULT CELLS AND PLACENTAL STEM CELLS CO-CULTURE. WORKING TOGETHER IS ALWAYS THE BEST WAY TO GO. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, R Buiga, D Mihu, VI Pop, Carmen Mihaela Mihu. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):999-1004.
170. METFORMIN PLUS PIAF COMBINATION CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA. B. Petrushev, **C. Tomuleasa**, O. Soritau, M. Aldea, T. Pop, S. Susman, G. Kacso, I. Berindan-Neagoe, A. Irimie, V. Cristea. Experimental Oncology, 2012, 34(1):17-24.
171. ESTABLISHMENT OF AN EMBRYONIC STEM CELL LINE FROM BLASTOCYST STAGE MOUSE EMBRYOS. Eموke Pall, I Groza, M Cenariu, Olga Soritau, Elen Gocza, **C Tomuleasa**. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):1005-1010.
172. MINIMALLY INVASIVE ENUCLEATION WITH ZERO ISCHEMIA FOR MALIGNANCIES. THE CLUJ NAPOCA EXPERIENCE. Gherman V, **Tomuleasa C**, Irimie A, Coman I. American Journal of Case Reports 2013;14:511-2.
173. BICYTOPENIA AS A PARANEOPLASTIC SYNDROME FOR PSEUDOMYXOMA PERITONEI. HEMATOLOGIC MANIFESTATIONS OF A SUBTLE DISEASE. **Ciprian Tomuleasa**, Bobe Petrushev, Madalina Vedean, Alexandru Irimie, Florin Zaharie, Ana Maria Rosu, Delia Dima, Andrei Cucuianu, Ioana Frinc. International Journal of General Medicine 2015, 8:93-5.
174. FIRST SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ROMANIA. Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Romanian Journal of Internal Medicine 2016, 2016 Sep 1;54(3):194-200.
175. PROCEEDINGS FROM THE 1ST INSIGHTS IN HEMATOLOGY SYMPOSIUM, CLUJ NAPOCA, ROMANIA MARCH 11-12, 2016. Anca Bojan, Ioana Berindan-Neagoe, Stefan Ciurea, Delia Dima, Shigeo Fuji, Gabriel Ghiaur, Ravnit Grewal, Emmet McCormack, Alina Tanase, Adrian Trifa, Ciprian Tomuleasa. Romanian Journal of Internal Medicine 2016 Sep 1;54(3):157-160.
176. TRANSTHORACIC ULTRASONOGRAPHY FOR THE IMMUNOCOMPROMISED PATIENT. Ioana Frinc, Petru Iliș, Delia Dima, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Bobe Petrushev, Cristian Berce, Mihai-Stefan Muresan, Cosmin Lisencu, Ioana Berindan-Neagoe, Anca Bojan, **Ciprian Tomuleasa**. Romanian Journal of Internal Medicine, 2016, in press.
177. ADVANCES IN THE TREATMENT OF NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS. Liren Qian, **Ciprian Tomuleasa**, Ioan-Alexandru Florian, Gheorghe Ungureanu, Ioan-Stefan Florian, Mihnea Zdrengea, Jianliang Shen, Delia Dima. Blood Res 2017; 52(3): 159-166

178. HYPEREOSINIPHILIA IN A PATIENT WITH PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED. Minodora Desmirean, Dalma Deak, Ioana Rus, Delia Dima, Sabina Iluta, Alexandra Preda, Tiberiu Moldovan, Andrei Roman, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2019, in press.
179. CORRELATION BETWEEN PREVALENCE OF T-CELL LYMPHOMAS AND ALCOHOL CONSUMPTION. Minodora Desmirean, Cedric Richlitzki, Sergiu Pasca, Patric Teodorescu, Sebastian Rauch, Jacob Steinheber, Sabina Iluta, Jiaxin Liu, Delia Dima, Ravnit Grewal, Weina Ma, Liren Qian, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2021, in press.
180. COEXISTENCE OF TRISOMY 8 AND 13 IN A NEWLY DIAGNOSED PATIENT WITH DIFFUSE LARGE B CELL NON-HODGKIN LYMPHOMA AND ACUTE MYELOID LEUKEMIA SECONDARY TO PRIMARY MYELOFIBROSIS. Horia Bumbea, Viola Maria Popov, Ciprian Tomuleasa, Meilin Omer, Camelia Dobrea, Irina Manea, Sabina Zurac, Cristiana Popp, Ion Dumitru, Madalina Simoiu, Bogdan Mastalier. Cureus 2022; 14(2): e22217.

1.

11.11.2024